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Abstract 
 
This dissertation was developed under the Curricular Traineeship scope, which took place at the 
University of Nottingham, between July 2016 and April 2017. Feline panleukopenia virus (FPV) and 
canine parvovirus (CPV), two closely related viruses, are known to cause acute enteritis in 
companion animals. Cats may be infected by strains of both viruses. Population-based surveillance 
studies have been lacking. This study investigated the prevalence of parvoviruses in a cross-
sectional survey of clinically-healthy cats housed within 13 shelters across the United Kingdom, 
comprising 818 faecal samples. FPV/CPV DNA was detected by PCR. Overall, the prevalence of 
parvovirus was 3.8%. Five FPV/CPV-2a like strains and one CPV-2b were identified by sequence 
analysis. These results showed that parvoviruses are circulating in the UK feline population, 
providing an insight about parvovirus occurrence in a non-clinical population, which reinforces the 
possibility that asymptomatic cats may be important reservoirs for infection maintenance in 
companion animals. 
 
 
Keywords: canine parvovirus; feline panleukopenia virus; viral genetic variants; United Kingdom 
 
Resumo 
 
Vigilância molecular dos Parvovírus circulantes em gatos no Reino Unido  
 
 
Esta dissertação foi elaborada no âmbito do Estágio Curricular, realizado na Universidade de 
Nottingham, entre julho de 2016 e abril de 2017. O vírus da panleucopénia felina (FPV) e o 
parvovirus canino (CPV), dois vírus estreitamente relacionados, são conhecidos por causar enterite 
aguda em animais de companhia. Os gatos podem ser infetados por estirpes de ambos os vírus. 
Investigou-se a prevalência de parvovirus através de um estudo transversal em gatos clinicamente 
saudáveis acolhidos em 13 abrigos de distintas localizações no Reino Unido, somando 818 
amostras fecais. O DNA do FPV/CPV foi detetado por PCR. Globalmente, a prevalência de infeção 
por parvovirus foi de 3,8%. Cinco estirpes virais compatíveis com FPV/CPV-2a e uma estirpe CPV-
2b foram identificadas através de sequenciação. Os resultados comprovam que diferentes variantes 
de parvovirus circulam na população felina do país, reforçando a possibilidade de gatos 
assintomáticos constituírem reservatórios importantes para manutenção da infeção em animais de 
companhia. 
 
Palavras-chave: parvovírus canino; vírus da panleucopénia felina; variantes genéticas virais; Reino 
Unido
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The following dissertation is based on the research work developed under the frame of the 
Curricular Traineeship Unit, part of the Integrated Master in Veterinary Medicine, from the 
University of Évora. 
The traineeship took place at the School of Veterinary Medicine and Science, Faculty of 
Medicine & Health Sciences, University of Nottingham – Sutton Bonington Campus, United 
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The traineeship included the research planning, development of laboratory experiments and 
critical evaluation of results, on an independent-work basis, supervised by members of Infection 
and Immunity Research Theme – Virology Group, which included Dr Janet Daly, Associate 
Professor in Emergent Viruses, as main research supervisor, and Dr Steve Dunham, Associate 
Professor of Veterinary Virology, as additional research supervisor.  
Laboratory training was delivered in the following laboratory techniques and procedures: 
o Mammalian cell culture, cell infection and cryopreservation techniques; 
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I. Literature Review 
1. Introduction 
1.1. Initial Characterization and Classification 
 
The published history of the parvoviruses begins in 1959, after Kilham and Olivier 
reported the isolation of a small, stable virus, initially named rat virus (RV), later known as Kilham 
Rat Virus (KRV), from lysates of an experimental rat tumour.1 
In 1966, Brailovsky first introduced to the literature the name “parvovirus”, derived from 
the Latin “parvus” meaning small, and named RV as “Parvovirus ratti”, in an early effort to start a 
Latinised binomial nomenclature system for viruses.2 During the 1970s, a working-group from the 
International Committee on the Taxonomy of Viruses (ICTV) established and approved the 
taxonomic family Parvoviridae, which then advanced the taxonomic rules for the further 
subdivision of this rapidly expanding family.3 
The family Parvoviridae nowadays includes two subfamilies: the subfamily Densovirinae, 
which contains viruses of invertebrates, and the subfamily Parvovirinae, with viruses that infect 
vertebrates.4,5 There are five genera in the subfamily Parvovirinae, taxonomically grouped 
according to their molecular properties. The genus Protoparvovirus includes the Feline 
Panleukopenia Virus (FPV) and the closely related Canine Parvovirus (CPV).5,6 
1.2. Viral structure 
1.2.1. Genetic structure 
The parvoviruses are both small and genetically simple. The genome consists of a single 
molecule of linear single-stranded DNA (ssDNA) of about 5,200 nucleotides (approximately 5 
kilobases) in length, which has two open reading frames (ORFs). The first ORF encodes two non-
structural proteins, NS1 and NS2, which are required for DNA transcription and replication.4,7 The 
second ORF encodes two structural proteins of the capsid, VP1 and VP2 (Fig.1).6 CPV and FPV 
only package the negative-sense DNA strand into the capsid. The genome has terminal 
palindromic sequences, enabling each end to form the hairpin structure required for replication of 
the viral DNA.4 
 
 
Figure 1. The genetic structure of CPV 
and FPV. (Reproduced from Fenner’s 
Veterinary Virology, 20164) 
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1.2.2. Capsid structure 
Nearly all the biological differences between CPV and FPV are determined by the viral 
capsid. In fact, its nucleotide sequences are around 98% identical.8–10 
The structures of the FPV and CPV capsids have been determined by a combination of 
protein analysis, electron microscopy, and lately by X-ray crystallography.11,12 The parvovirus 
capsid is a icosahedral structure exhibiting T=1 symmetry that is assembled from a total of 60 
copies of viral proteins, VP1 and VP2, of which approximately 90% is VP2 and 10% being the 
VP1 protein.4,6  
The two proteins most likely act in a structurally equivalent way, being formed by 
alternative splicing of the same messenger RNA (mRNA). The entire sequence of VP2 is encoded 
within the VP1 gene.12 
The surface of the capsid is structurally complex and includes features such as a raised 
area (spike) surrounding the three-fold axis of symmetry, a depression (dimple) spanning the two-
fold axis of symmetry, and a further depressed area (canyon) surrounding the five-fold axis of 
symmetry of the capsid (Fig. 2).11,12  
The receptor binding site of feline and canine parvoviruses, which determines their host 
and tissue tropism, is the three-fold spike, which is also the site of binding of most antibodies 
directed against the capsid.4,12 The VP2 monomers make up most of the outer surface of the virus 
particle and are responsible for receptor binding, antigenic properties, and environmental 
stability.6  
 
 
 
Resistance to inactivation by organic solvents indicates that parvoviral capsids lack 
essential lipids. Indeed, parvoviruses are extremely stable to environmental conditions, including 
extremes of heat and pH.4  
Figure 2. Structure of the Parvovirus capsid. (Reproduced 
from Allison et al., 201613) 
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1.3. Viral Replication 
 
Parvoviruses infect cells by binding to the Transferrin Receptor (TfR) type-1 on the cell 
membrane.6,12 TfR has been described as the crucial and, apparently, only receptor required by 
parvoviruses for binding and infection of carnivore host cells.5,13 After binding, virions are then 
taken up into the cell by rapid clathrin-mediated endocytosis. After entering the cell, virions traffic 
through the endosomal pathways within the cytoplasm.12 
Exactly how the particles exit from the endosomal system is still unclear, however, this 
event causes the exposure of the capsid to lower pH as the endosome acidifies, probably causing 
the release of some of the capsid-bound calcium ions and movement of capsid loops, which 
facilitates the release of the VP1 unique region.5,12 Additionally, the viral VP1 protein contains a 
phospholipase-enzyme activity, which may be involved in modifying the endosomal membrane 
and facilitating capsid release.4 
The viral particles are trafficked to the nuclear pore, which allows entry into the nucleus, 
where the viral DNA replication and capsid assembly occurs, requiring a host-cell function of the 
S phase of the cell division cycle.10 This requirement for mitotic cycling cells is explained by the 
need for DNA replication machinery, because the virus does not encode or package an enzymatic 
system for replication. Therefore, the cellular DNA-polymerases replicate the viral DNA in a 
double-stranded form, which is used as a template for transcription of viral mRNAs.4 
Subsequently, alternative splicing generates several mRNA species, which are translated 
into four major proteins. The most abundant mRNA, which is encoded in the 5′ half of the genome, 
directs the synthesis of the structural proteins. The non-structural proteins are encoded in the 3′ 
portion of the genome.4,5 
It is known that the 3′-terminal hairpin on the negative-sense DNA genome acts as a self-
primer for the initiation of synthesis of a double-stranded DNA replicative intermediate. It is 
produced as two complete positive strands and two complete negative strands by a series of 
reopening of closed circular forms, re-initiation of replication, and single-strand endonuclease 
cleavages.4,5 This complex mechanism of replication of the genome is known as a rolling-hairpin 
replication, and some details are still not fully understood.4 
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2. Feline Panleukopenia Virus Infection 
2.1. Epidemiology 
 
Feline panleukopenia is caused by the feline panleukopenia virus (also designated as 
feline parvovirus)14,15 and was first described in 1928.16,17 It is genetically and antigenically closely 
related to mink enteritis virus (MEV), blue fox parvovirus (BFPV) and canine parvovirus (CPV). 
FPV infects domestic cats and other Felidae.14,18 Species from the families Mustelidae, 
Procyonidae, and Viverridae, which include raccoons, ring-tailed cats, minks and foxes, are also 
susceptible.19,20 Minor differences in the genome have been reported, but these appear to be 
clinically insignificant mutations.18,21 
The disease is characterised by severe reduction in circulating white blood cell count and 
enteritis with degeneration of the intestinal villi.17,22 The infection causes high mortality and 
morbidity, and it is considered highly contagious, with concentrations of up to 109 viral particles 
shed per gram of faeces from infected animals.17 
The virus is characterized by being ubiquitous and very stable, persisting in the 
environment over one year in organic material or fomites.23 Thus, indirect transmission plays a 
key role in the infection of susceptible animals, it being possible that owners carry viral particles 
potentially infecting cats housed entirely indoors. Contaminated litter trays, food dishes, bedding 
and infected cages can have a particular importance in shelter environments.17,24 Flies and other 
insect vectors can also be involved in the transmission of the disease.14 
Although environmental persistence is prolonged, the shedding period in the acute phase 
of the disease lasts up to two days, however, the faecal shedding period can easily reach six 
weeks after recovery, and consequently detection of faecal viral DNA does not necessarily signify 
an active infection.23 
The majority of infections are subclinical, and clinically healthy cats can demonstrate 
antibody titres up to one year of age.17 Susceptible cats that are exposed and infected during the 
first year of life represent the most common population for clinical disease.22,23 It is described that 
unvaccinated kittens that acquire maternally derived antibodies (MDAs) through colostrum are 
typically protected up to three months of age.18 
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2.2. Pathogenesis 
 
As previously explained for viral replication, parvovirus needs cellular DNA polymerase, 
requiring rapidly multiplying cells in the S-phase of division.4,23 Thus, lesions in feline hosts occur 
in tissues with a high rate of mitotic activity.14 The most commonly affected tissues in adult animals 
are the bone marrow, lymphoid tissue and intestinal mucosal crypts.17 
Transmission occurs by the faecal-oral route, with replication occurring in the oropharynx 
initially. A viraemic phase, occurring between two and seven days, distributes the virus throughout 
the different tissues.14,25 FPV leads to immunosuppression through immune cells depletion, due 
to the infection of lymphoid tissues. In cats, up to nine weeks of age, thymic involution and 
degeneration is described.14 
Viral replication in the bone marrow occurs in early progenitor cells, affecting all the 
myeloid cell populations. This pathogenesis feature actually reflects the panleukopenia 
designation in cats infected with FPV.23 
FPV causes damage to the rapidly replicating cells of the intestinal mucosa crypts in 
clinically-affected cats, causing destruction of the intestinal villi, which may lead to diarrhoea 
related with malabsorption and increased permeability (Fig.3).22,25 The most affected intestinal 
segments are the jejunum and ileum.17 
Cats infected with FPV are susceptible to secondary bacterial infections with enteric 
bacteria, causing Gram-negative endotoxaemia and possibly bacteraemia.17,23 It is described that 
co-infections increase the severity of FPV infection in cats.26 FPV can act as an 
immunosuppressive agent due to leukopenia and intestinal lesions, allowing bacterial 
proliferation. Both Clostridium piliforme, which is the causal agent of Tyzzer’s disease, and 
salmonellae infections are reported to increase the mortality rate in FPV clinical infections.23  
Dual infections of viral agents, such as Feline Calicivirus (FCV) or Feline Astrovirus, can 
be associated with high severity of the disease.17,27 When endotoxemia occurs, it is described 
that cats can develop disseminated intravascular coagulation (DIC) as a secondary 
complication.17,23  
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In utero infection in early pregnancy can produce a spectrum of reproductive disorders, 
including fetal death, resorption, abortion, and mummified fetuses.25 It is described that closer to 
the end of gestation, FPV infections can result in birth of live kittens with different degrees of 
damage to the neuronal tissue.14 Within the same litter, some kittens are apparently unaffected 
(clinically healthy) due to innate resistance or acquisition of MDA, however these kittens may 
harbour the virus sub-clinically up to two months after birth.18 
The central nervous system (CNS), including the cerebrum, retina and optic nerve, can 
be affected in late prenatal and early neonatal infection. Cerebellar damage very often results in 
cerebellar hypoplasia, which can be explained by the fact that the cerebellum develops during 
late gestation and early kittenhood.25  It is described that the CNS may be affected by infections 
occurring up to nine days of age, interfering with the cortical development and resulting in reduced 
and distorted cell layers in the cerebellum.14 
Parvoviral particles have been detected in the CNS of affected cats by immunochemical 
staining, and FPV was also detected in the cerebellum of both adult and young affected cats by 
polymerase chain reaction (PCR).17 It is described that Purkinje’s cells of the cerebellum are 
especially susceptible to FPV infection, as these cells express transferrin receptors that are used 
by parvoviruses for cell entry28; even though as post-mitotic cells they should not allow viral 
replication, viral antigens were detected after experimental infections in new-borns.22,23 
Interestingly, although neurons are terminally-differentiated cells, parvoviruses seem to 
be able to replicate in these cells.14,23Parvovirus has been detected by histochemical methods 
Figure 3. Parvovirus-infected villus showing collapse and necrosis of intestinal 
villus.(Reproduced from Infectious Diseases of the Dog and Cat, Greene, 2012.52 “Art 
by Dan Beisel and Kip Carter © 2004 University of Georgia Research Foundation Inc”) 
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and PCR in the brains of adult cats that died of various diseases, including panleukopenia, yet 
the clinical significance is unclear.29 
A link between myocarditis and parvovirus infection has been reported in neonatal 
infections in dogs, however, in cats, the role of FPV in myocarditis is not completely explained.23 
Data have been reported suggesting that FPV is important in the pathogenesis of cardiac disease, 
with one study that identified FPV DNA in a significant number of adult cats that had died from 
cardiomyopathy.30 However, a recent study suggested that parvovirus was not significantly 
associated with myocarditis in kittens, although it is unclear  so far whether the myocardium is a 
replication site in infected kittens.31 
2.3. Clinical Findings 
 
The frequency of cats that exhibit clinical disease caused by FPV infection has been 
reported  much lower than the number of cats infected with the virus, which can be explained by 
the high prevalence of FPV antibodies in the cat population.23 Thus, subclinical cases are more 
common in older susceptible cats.14 
The severity of the clinical disease depends on age, immune status and concurrent 
infections. The clinical disease is common in young unvaccinated kittens, particularly between 
three and five months of age, but sudden neonatal or young death has been described in kittens 
of four weeks to 12 months of age in vaccinated cats. In the United Kingdom (UK), it has been 
reported that FPV was the cause of 25% of kitten mortality, representing a significant clinical 
illness in  the domestic cat population.32 
The disease is characterized by an acute self-limiting development. In the peracute form 
of the disease, cats can die with few or no premonitory signs, within 12 hours. In these cases, 
affected kittens may be found in septic shock, profoundly dehydrated, hypothermic and 
comatose.23  
Typically, the disease assumes the acute form, presenting initially non-specific signs, 
such as fever, lethargy, anorexia and dehydration. Vomiting is a common finding in the course of 
the illness, which is often bile-tinged and occurs unrelated to eating.14 Later, watery to 
haemorrhagic diarrhoea can be present, however it is less common.17 
On physical examination, pain may be noted during palpation of the abdomen, and a 
hunched posture is frequently observed. In severely affected cats, bloody diarrhoea, oral 
ulceration and mucosal pallor may be present.17 In terminal stages, affected cats may be 
hypothermic, bradycardic, and comatose. Cats often die of complications associated with 
dehydration, secondary bacterial infection and DIC.23 When infected cats survive for longer than 
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five days without developing fatal complications, they usually recover, although full recovery can 
take several weeks.22 
Neonatal kittens usually have neurological signs, exhibiting tremors, incoordination, 
ataxia, decreased postural reactions and hypermetric movements, but normal mental status, 
which is typical of cerebellar disease14,17. Not all kittens of the same litter are affected or have the 
same degree of neurologic deficits. Examination of the ocular fundus of kittens with neurological 
signs may reveal retinal lesions.23 
2.4. Diagnosis 
2.4.1. Clinical Laboratory Findings 
Diagnosis of systemic feline panleukopenia is generally based on clinical signs and the 
presence of leukopenia, which is due to neutropenia and lymphopenia. Total leukocyte counts 
during the course of infection are usually between 50 and 3000 cells/μL.17 However, leukopenia 
is not pathognomonic for FPV infection, as it may not occur in all clinical cases. Neutropenia often 
develops first as neutrophils exude into the infected intestinal tract. It is followed by leukopenia, 
as a result of bone marrow suppression.23 Thrombocytopenia, which may result from damage to 
the bone marrow, can be found with other coagulation abnormalities in cats that develop DIC. 
Marked anaemia is uncommon in feline panleukopenia, except in cases with severe intestinal 
blood loss. Recovery may be associated with neutrophilia with a left shift, due to the resurgence 
of leukopoiesis.22,23 
Serum biochemical findings are typically nonspecific. Hypoalbuminemia and 
hypocholesterolaemia may be found. Electrolyte abnormalities, such as hyponatremia, 
hypochloraemia and hyperkalaemia can also be present. In more severe cases, azotaemia is 
frequently found, related with pre-renal and non-renal causes such as dehydration. Increases in 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST), or hyperbilirubinemia 
may also be present, reflecting hepatic involvement.17 
In kittens with neurological signs, magnetic resonance imaging or computed tomographic 
scanning can help to visualize cerebral or cerebellar cortical findings.23 
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2.4.2. Diagnostic Assays 
2.4.2.1. Serologic Testing 
Widespread exposure and immunization constrain the use of serological testing as a 
diagnostic tool for feline panleukopenia. Thus, serologic assays that detect FPV-antibodies are 
generally used to evaluate the need for vaccination. Hemagglutination inhibition (HI), which 
measures the ability of serum to prevent agglutination of erythrocytes by the virus, and serum 
neutralization assays may be used.23 These tests can be used in outbreak situations, or in shelter 
environments, to assess which cats are at risk of  developing  disease and virus shedding, 
distinguishing from cats which are protected, and consequently, are at lower risk of infection.14 
2.4.2.2. Faecal Parvovirus Antigen Testing  
FPV antigen can be detected in faeces using immunological methods, with Enzyme 
Linked Immunosorbent Assay (ELISA) based tests, and with immunochromatographic tests, both 
commercially available for detection of CPV-2 antigen in faeces or intestinal contents.17,33 
Detection of the FPV antigen by CPV-2 designed tests is due to the close structural and antigenic 
relationship between FPV and CPV-2 strains.34 These assays represent a practical indicator of 
FPV infection in kittens. However, the sensitivity and specificity of in-house test systems may vary 
between the commercially available assays and with the stage of infection, as virus shedding may 
be transient.35 
Usually, false-negative results are more common using these assays than false-positives, 
therefore a positive test result in a cat exhibiting clinical signs suggests a diagnosis of feline 
panleukopenia. In addition, it was reported that sensitivity of commercially available tests ranged 
from 50% to 80%, and specificity  between 94% and 100%, when compared with faecal electron 
microscopy using feline samples.33 Nevertheless, these assays are usually only able to detect 
FPV in faeces up to 48 hours after infection thus, by the time of the onset of clinical signs, the 
virus may no longer be detectable. In addition, false-positive results, although infrequent, can 
result from the administration of attenuated live viral vaccines up to two weeks after 
immunization.35,36  
2.4.2.3. Virus Isolation 
FPV can be isolated in feline cells, however, isolation can be difficult and the virus usually 
shows minimal cytopathic effects, being more easily demonstrated in young, rapidly multiplying 
cells.17 Thus, viral isolation is not often used for diagnosis, remaining an important research tool. 
2.4.2.4. Faecal Electron Microscopy 
Faecal Electron Microscopy (EM) can help in the diagnosis of viral enteritis, enabling the 
diagnosis of other infections, caused by agents such as rotavirus and coronavirus.23 However, 
the application of this tool in clinical diagnosis is infrequent, as the turnaround time may be slow, 
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technical expertise and expensive equipment are required, resulting in large costs associated 
with the diagnosis. 
2.4.2.5. Molecular Diagnosis 
PCR can be used to identify FPV in whole blood, faecal, intestinal and tissue samples 
from cats.14 Testing of whole blood is recommended in cats without diarrhoea or when no faecal 
samples are available. Genetic detection is considered the gold standard, being particularly 
valuable when viral quantities are low, allowing confirmation of the diagnosis when negative test 
results are obtained with commercially available in-clinic kits23,35,36 
The sensitivity of these assays is high, so the virus can be identified for longer periods 
using molecular methods.14 Also, genetic detection allows subclinical detection and positive 
results can be found after modified-live virus (MLV) vaccines, which are an important feature to 
research, but clinically, positive results should be interpreted with respect to recent MLV 
vaccination, relating with compatible clinical signs and haematological alterations.23,37 
More recently, real-time PCR assays have been developed for detection of FPV and 
differentiation of FPV from CPV-2 strains, and to distinguish field and vaccine strains.38 
2.5. Pathological Findings 
 
Gross pathological changes may include focal ulceration on the surface of the tongue. 
The intestinal tract can be visibly dilated, with thickening, distention and hyperaemic intestinal 
walls, often presenting serosal haemorrhage. Intestinal contents may be bloody with a fetid 
odour.22 Mesenteric lymph nodes can be oedematous. In some cats, mild pleural or peritoneal 
effusion may be present.17 Prenatally infected cats commonly present a small cerebellum, and 
more rarely hydrocephaly. Thymic atrophy is also a common finding.25 
Histopathological findings in the intestine include dilated crypts, necrosis of crypt 
epithelial cells, accumulation of cellular debris with crypt dilation and neutrophil infiltration. 
Shortening of villi occurs secondary to the necrosis of crypt cells and submucosal oedema is often 
present.14 The jejunum and ileum present the most severe histopathological lesions. Acutely-
affected cats often show lymphocyte depletion in lymph nodes follicles, Peyer’s patches, and 
spleen. Usually, lymphoid atrophy is present with concomitant mononuclear phagocyte 
hyperplasia. In some cats, intranuclear inclusions can be found. Bone marrow examination may 
reveal hypoplasia.25 
In prenatally or neonatally infected kittens, histological findings of the cerebellum include 
marked cerebellar degeneration and reduced population of the granular and Purkinje’s cell layers. 
Myelin degeneration in the lateral funiculi of the spinal cord is often found.28 
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2.6. Therapy and Prognosis 
 
Treatment of cats with feline panleukopenia is mainly supportive, particularly with 
intravenous crystalloids and parenteral antimicrobial therapy, as further described for CPV-2 
infections in dogs. Parvovirus cases should be hospitalised in isolation facilities to avoid 
transmission of infection.17,23 
With the objective of replacing lost electrolytes, correct dehydration, and meeting daily 
maintenance needs, parenteral fluid therapy is recommended. Ideally, lactated Ringer’s solution 
can be used, and potassium supplementation can be valuable. Blood glucose concentration 
should be monitored, and dextrose supplementation may be needed accordingly.39  
Until vomiting has ceased, oral intake of food and water should be withheld, which 
indirectly slows the bowel mitotic activity necessary for viral replication. To control persistent 
vomiting, metoclopramide or ondansetron are effective. Additionally, gastrointestinal protectants 
are described to coat the bowel, but should not be given to vomiting animals.23 
Glucocorticoid therapy is not generally recommended, due to the immunosuppressive 
effects. In cats with severe anaemia, hypotension, or hypoproteinaemia, plasma or blood 
transfusion therapy is advised. In addition, a low-dose subcutaneous heparin therapy is 
described, when thrombocytopenia and severe coagulopathy are present.17 Antiserum or high-
titre parvoviral antiserum from vaccinated or recovered cats are useless after the onset of clinical 
signs.39 
Antimicrobial agents, effective against gram-negative and anaerobic bacteria, may be 
administered to control secondary bacterial infection. Broad-spectrum antimicrobial agents, such 
as ampicillin or cephalosporin can be sufficient for non-complicated cases.23 In severe cases with 
septic complications, a combination of a penicillin (penicillin or amoxicillin-clavulanate), 
metronidazole or clindamycin, which are chosen according to the anaerobic spectrum required, 
with aminoglycosides, for gram-negative spectrum, may be needed.17 However, due to 
nephrotoxic potential of the aminoglycosides, their use must be avoided. In addition, quinolones 
can be also considered, nevertheless due to cartilaginous toxicity in growing animals and retinal 
toxicity, particularly in cats, their use must be carefully considered and, avoided whenever 
possible. Lower toxicity single agents that can be effective against both anaerobes and gram-
negative bacteria, such as third-generation cephalosporins can be considered, however these 
agents are usually more expensive.14,22 
In cats with feline panleukopenia, parenteral therapy with a B complex-vitamins 
combination is described, due to high requirements for B-vitamins, decreased food intake and 
loss in diuresis, preventing development of thiamine deficiency.23 
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In contrast to canine parvoviral enteritis, treatment with recombinant feline interferon 
(rfIFN-ω) has not been proven beneficial for treatment of feline panleukopenia.40 However, it may 
be useful when administered to queens before vaccination, increasing MDA levels for passive 
transfer, and to kittens before they are introduced into contaminated environments, such as 
shelters.41  
Response to therapy should be monitored, using leukocyte counts, as leukopoiesis 
usually resurges after up to 48 hours.23 Oral intake of food should be started by frequent feeding 
of small quantities of bland food.14  
Cats that survive the first 5 days of treatment generally recover, albeit it is described that 
recovery is frequently more prolonged than parvoviral enteritis in dogs. One study in Europe 
reported  a survival rate of cats with feline panleukopenia of  51%.42  
Cats with white cell counts below 1000/μL were almost twice as likely to die, compared 
with those with white cell counts above 2500/μL.17 Only total leukopenia (and not lymphopenia) 
was correlated with mortality. In addition, both hypoalbuminemia and hypokalaemia were 
associated with an increased risk of mortality. Moreover, mortality in cats does not seem to be 
correlated with age, contrasting to what happens in dogs with parvoviral enteritis.42 
2.7. Immunity and Prevention 
 
Recovery from feline panleukopenia is described to confer lifelong immunity. However, 
the crucial factor to reduce the incidence of the disease is parenteral vaccination.18  
Vaccination is recommended for all cats, regardless of lifestyle (indoor/outdoor), due to 
the gravity of the illness, its ubiquitous distribution and the high resistance of the virus in the 
environment. Inactivated and attenuated live viral vaccines are available to successfully prevent 
feline panleukopenia.18,23 Both types of vaccines elicit protection with high antibody titres, 
however the attenuated live vaccine may be more rapid and efficient at inducing protection than 
the inactivated vaccine.43 
With modified-live virus (MLV) vaccines, when MDA interference does not occur, 
immunity occurs up to 1 week after the first vaccination and lasts for at least 3 years, however it 
has been described that immunization can provide lifelong protection .44,45 In addition, two doses 
after 3 to 4 weeks are recommended for the initial vaccination course, as maximal immunity only 
occurs 1 week after the second vaccination boost.17 
Inactivated vaccines have the advantage of being safe in pregnant queens and kittens 
younger than 4 weeks and should be reserved for these situations. In addition, MLV vaccines can 
represent a risk to immunocompromised cats with acquired deficiencies, such as feline 
immunodeficiency virus infection, due to the possibility of vaccine-induced illness. Therefore, 
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inactivated FPV vaccines, which have minimal risk, should be used in immunocompromised 
cats.23,46 
Oral vaccination with a  MLV vaccine has been shown to be ineffective.23,47An intranasal 
MLV trivalent FPV vaccine has been available and is able to produce active immune response. 
However, it is not as effective as parenteral MLV vaccines, and an outbreak associated with their 
administration has been reported48.  The use of intranasal vaccination against FPV is therefore 
controversial.17,18 
Usually, vaccination schemes start at eight  to nine weeks of age, and are followed by at 
least one more MLV vaccine administration or two more inactivated vaccines, between two to four 
weeks thereafter, with the last vaccine given between 14 to 16 weeks of age, avoiding vaccine 
failure by prolonged interference by MDA.49 Although vaccination against panleukopenia was 
recommended annually in the past,  different studies showed that vaccination protected against 
challenge with virulent FPV for longer than a year44,45 The Vaccination Guidelines Group of the 
World Small Animal Veterinary Association (WSAVA) currently recommends, after the first 
vaccination course, a booster after one year and subsequent triennial vaccination thereafter. 
Multivalent vaccines that contain FPV antigen, combined with those of feline respiratory viruses, 
rabies viruses and Feline Leukaemia Virus (FeLV) are commercially available.49,50 In shelters, the 
use of MLV vaccines is recommended, due to the rapid onset of immunity.17,18 
Environments with high levels of contamination, such as breeding catteries and shelters, 
are high risk environments for infection.24 New kittens should not be introduced into households 
that previously contained cats infected with FPV unless they are fully vaccinated.17 In an outbreak 
situation, passive immunotherapy, administering  high antibody serum can protect exposed and 
unvaccinated kittens for two to four weeks, however this strategy is only effective before the onset 
of possible clinical signs, and subsequent vaccination should be done after 3 weeks.39 
Disinfection procedures are essential to prevent or control an outbreak, which should be 
done with diluted household bleach (dilution of 1:30) on all tolerable surfaces that should be 
exposed for at least 10 minutes. Similarly, utensils and bedding should be washed with added 
bleach.23 Moreover, in shelters and catteries, it is important to isolate cats that develop 
gastrointestinal illness in separate housing from healthy kittens.41 
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3. Canine Parvovirus Infection 
3.1. Epidemiology 
 
Canine parvovirus is the most widely recognized cause of transmissible viral diarrhoea in 
dogs and one of the most common infectious diseases of dogs worldwide, being the most 
prevalent virus in dogs with infectious diarrhoea.51,52 This highly contagious and often deadly 
disease is caused by the strains of Canine Parvovirus Virus type-2 (CPV-2), which include the 2, 
2a, 2b, and 2c variants.53,54 CPV-2 was first reported in 1978, and its variants are distinct from 
CPV-1, also called Minute Virus of Canines (MVC), which belongs to the genus Bocavirus and is 
assumed to have minimal pathogenic potential, although it has been related with neonatal death 
and gastrointestinal signs in dogs.54–56 
It has been described that Canidae members are susceptible, as natural CPV infections 
have been reported in domestic dogs (Canis familiaris), bush dogs (Speothos venaticus), coyotes 
(Canis latrans), wolves (Canis lupus) and other family members.52,57 
Although the original CPV-2 is only related with intestinal and systemic infection in dogs, 
the evolved strains 2a, 2b, 2c may infect felids under experimental and natural conditions.37,58 
Similarly to FPV, most infections occur as a result of contact with contaminated faeces in the 
environment, considering that parvovirus is highly resistant in the environment and survives at 
least up to 1 year in infected organic material.22 Fomites also represents an important means of 
infection, and insects and rodents can serve as mechanical vectors for virus spread.59 
The incidence of severe disease and death can be very high in susceptible animals 
however, acute enteritis is found in dogs of any breed, age, or sex.60 Outbreaks of severe 
gastroenteritis and mortality caused by CPV-2c infections in adult dogs (more than 6 months old) 
have been described.54 Nevertheless, pups between 6 weeks and 6 months of age, and especially 
those less than 12 weeks of age, are more likely to develop severe illness.60  Disease can also 
occur in unvaccinated or improperly vaccinated adult dogs.54,59 Rottweilers, Doberman pinschers, 
Labrador retrievers, American Staffordshire terriers, German shepherds, and Alaskan sled dogs 
seem to have an increased risk for severe CPV enteritis.60,61 However, reasons for breed 
susceptibility are still unclear. The common ancestry of Doberman pinschers and Rottweilers has 
been implicated in their susceptibility to severe disease as both breeds have a relatively high 
prevalence of  von Willebrand’s disease (VWD), and inherited immunodeficiency.62 
In the field, the incubation period of the original CPV-2 strains was seven to 14 days, and 
the emerged strains (2a, 2b, 2c) are associated with an incubation period of four to six days.23,63 
The infection does not inevitably result in apparent disease, some cases of naturally-infected dogs 
have been reported as never developing overt clinical signs, especially in the presence of residual 
MDA.54,63 
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3.2. Pathogenesis 
 
The pathogenesis of parvovirus infections is influenced primarily by the requirement for 
rapidly multiplying cells, in S-phase of division, for successful infection to occur. 22,23 
Similarly to what happens in FPV infections in cats, from 18h to 24h after intranasal or 
oral infection, the virus initially replicates in the oropharynx, tonsils and other lymphoid tissues. 
Infection of lymphoid tissues leads to their necrosis. Between one and five days after infection, 
virus spreads systemically through viraemia.25 Subsequently to the viraemia, a widespread 
infection occurs, with damage in rapidly-dividing cells of the gastrointestinal tract, thymus, lymph 
nodes, and bone marrow. Circulation of infected lymphocytes can carry the virus to different 
tissues, which allows the detection of CPV in the lungs, spleen, liver, kidney, and myocardium.54,59 
Affected gastrointestinal tissues include the epithelium of the tongue, oral cavity, 
oesophagus, and intestinal tract.52 The primary site for viral replication is the germinal epithelial 
cells of the intestinal crypts, causing destruction and collapse of the epithelium.62 Cell turnover is 
reduced and the villi become shortened, which leads to malabsorption and increased 
permeability, resulting in profound enteritis and diarrhoea.25,52 Secondary bacterial infections from 
gram-negative and anaerobic microflora play a key role in the pathogenesis of the disease, which 
may lead to bacteraemia, endotoxemia, and DIC.52,62 
CPV infection causes destruction of the active precursors of circulating leukocytes and 
lymphoid cells, leading to neutropenia and lymphopenia, which is often more pronounced than 
neutropenia.23,59 Neutropenia results not only from infection of the marrow but also sequestration 
of neutrophils in damaged gastrointestinal tissue.25,59 Death can occur as quickly as 24 hours after 
the onset of clinical signs, especially in younger animals.22 
Besides the factors related to the age of the animal, immunity and breed, other 
pathogenesis factors associated with the route of exposure, viral dose, and strain virulence, 
leading to different grades in the severity of clinical signs in affected dogs.22 
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3.3. Clinical Findings 
 
CPV infection has been associated with three main tissues — GI tract, bone marrow, and 
myocardium — however, the skin and nervous tissue can also be secondary affected.52 In 
addition, other clinical complications as secondary bacterial infection or thrombosis can occur.59  
A marked variation is found in the clinical response of dogs to intestinal infection with 
CPV, ranging from unapparent infection to acute fatal disease. Unapparent, or subclinical, 
infection occurs in most dogs, mainly in puppies with intermediate MDA titres that can protect 
from disease but not from infection. CPV enteritis can progress rapidly, especially with the CPV-
2 strains.52,62 
Physical examination of puppies with parvoviral enteritis frequently reveals fever, 
lethargy, weakness, dehydration, and abdominal pain. Vomiting is frequently severe, and is 
followed by diarrhoea, anorexia, and rapid onset of dehydration.52,62 Diarrhoea is often liquid, foul-
smelling, and may contain streaks of blood or frank blood.22 
Abdominal palpation may reveal a tubular mass, the consequence of intestinal 
intussusception. Ulcerative glossitis may occur in some puppies. Mucosal paleness, prolonged 
capillary refill time, or rarely hypothermia can be observed in some dogs. Septic shock may be 
associated with tachycardia or bradycardia, and poor pulse quality.59 
The presence of co-infections, as seen in pups with intestinal helminths, protozoa, and 
enteric bacteria such as Clostridium perfringens, Campylobacter spp., and Salmonella spp. can 
influence the severity of the disease.52,64 
Primary neurological disease in puppies with parvoviral enteritis may result from hypoxia 
secondary to myocarditis, hypoglycaemia, or intracranial thrombosis or haemorrhage, during the 
disease process, sepsis, or acid-base-electrolyte disturbances.59 Co-infection with viruses such 
as canine distemper virus (CDV) should also be considered.60,65  Cerebellar hypoplasia, which is 
common in kittens prenatally or neonatally infected with FPV, has been rarely associated with 
CPV in utero infection in dogs.14,22 However, generalized infection has been described in neonatal 
pups, with haemorrhage and necrosis within the brain, liver, lungs, kidneys, lymphoid tissues, and 
gastrointestinal tract.59,62 The DNA of CPV-2 variants has also been detected in the CNS of dogs 
without neurological signs, which could be associated with active replication of the virus in the 
nervous tissues, however further investigations are needed. 66 In addition, there have been 
sporadic reports of leukoencephalomalacia related with parvovirus.52 
Viral myocarditis can develop from infection in utero or in pups up to two weeks of age, 
which results in signs of sudden death or congestive heart failure, presenting clinical signs that 
may be delayed until two months of age.52 Clinical signs include tachypnoea and increased lung 
sounds, as consequence of congestive heart failure, although the spectrum of myocardial disease 
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in individuals is varied.59 Cardiac signs can occur preceded by parvoviral enteritis or may occur 
suddenly, without apparent illness. The widespread vaccination and exposure of adult animals, 
which develop strong humoral immune responses, has led to a significant decline in the incidence 
of myocarditis and neonatal complications of parvovirus infection, because of MDA protection.54,60 
Myocarditis is sporadically found in pups that do not nurse sufficiently, or are born from unexposed 
or unvaccinated bitches.62  
Erythema multiforme has been described in dogs with canine parvoviral enteritis. Skin 
lesions include generalized cutaneous and mucosal ulceration of the footpads, pressure points, 
mouth and genital mucosa. Erythematous patches on the abdomen and perigenital skin have 
been reported.59,67 
The predisposition to asymptomatic urinary tract infections, which is detected in 
approximately 25% of pups after CPV enteritis, was attributed to faecal contamination of the 
genitalia associated with neutropenia. Subclinical and not treated urinary tract infection can cause 
chronic urinary infection, as a secondary consequence.52 
3.4. Diagnosis 
 
The onset of foul-smelling, bloody diarrhoea, with or without vomiting, in a young dog 
(under two years of age) is frequently considered indicative of CPV infection.22,59 However, 
several other viral pathogens may cause diarrhoea in dogs, such as coronaviruses, adenoviruses,  
reoviruses and rotaviruses.52 Enteropathogenic or parasitic infections, alone or in combination, 
should also be considered.51,60 In kennels and shelters, a rapid diagnosis of CPV infection is 
especially important, allowing the isolation of infected dogs and preventing secondary infections 
of susceptible animals.54 
3.4.1. Clinical Laboratory Findings 
The most common findings in the complete blood count (CBC) are leukopenia, 
neutropenia, and lymphopenia. Toxic neutrophils and monocytopenia can also be present.59  
Even though leukopenia is not found in all cases, is proportional to the severity of illness at the 
time the blood is taken.68 
Thrombocytosis or, less frequently, thrombocytopenia can also occur. Anaemia can be 
present related with the gastrointestinal blood loss, which may be non-regenerative or become 
regenerative, however is not a consistent feature of infection.59 
The most frequent findings in the serum biochemistry panel in dogs with parvoviral 
enteritis are hypoproteinaemia, hypoalbuminemia, and hypoglycaemia. Electrolyte abnormalities 
such as hyponatremia, hypochloraemia, and hypokalaemia have been reported.59 Occasionally 
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severe dehydration results in prerenal azotaemia. Bacterial sepsis often causes 
hyperbilirubinemia and increased liver enzyme activities.68 
Coagulation abnormalities may include prolonged activated partial thromboplastin time, 
decreased antithrombin activity, and increased fibrinogen concentrations, leading to 
hypercoagulability.69 
 
3.4.2. Diagnostic Assays  
Suspected clinical cases should be confirmed by laboratory tests. Different methods are 
available for laboratory diagnosis of CPV infection. Faeces, or intestinal samples from necropsies 
are commonly used for the detection. Blood samples are more useful for the CPV viraemia in late 
stages of infection, as parvovirus viraemia can be long lasting.54,70 
3.4.2.1. Faecal Parvovirus Antigen Testing 
The faecal antigen ELISA is a commonly-used assay for diagnosis of canine parvoviral 
enteritis and it is available for in-hospital testing for CPV infection, performed on a rectal swab 
specimen. As previously described, these assays developed for CPV diagnosis can also detect 
FPV35, given the close genetic and antigenic properties. Different assays are available, which 
detect all CPV-2 variants including CPV-2c, but their sensitivity and specificities vary.54 
Faecal antigen ELISAs are specific but their sensitivity is particularly problematic.59 
Different studies were conducted to compare the sensitivity of three different commercially 
available faecal antigen assays. When compared to molecular assays, the relative sensitivity of 
the tests did not exceed 50%, while the specificity was 100%.71 In another study, comparing with 
molecular methods and immunoelectron microscopy, the low sensitivity and high specificity of the 
faecal antigen ELISA kits was confirmed.72 Although when comparing with molecular methods 
and immunoelectron microscopy, the specificity of all tests had been proven low; it had been 
demonstrated that these tests have a sensitivity between 77% and 80% on samples containing 
high CPV DNA loads (> 105 copies/mg of faeces, determined with real-time PCR).54 
The poor sensitivity can be explained by the period of faecal virus shedding, which 
corresponds to the first few days of clinical illness. The incubation period from four to six days 
interferes with early detection, and in late stages of infection (more than 10 days) low amounts of 
viral particles are shed, which are not often detected by ELISA73, especially considering that virus 
shedding can be intermittent and early appearance of high antibody titres in the intestinal lumen 
may sequestrate CPV particles.74 
Comparing with molecular assays and immunoelectron microscopy, the specificity of the 
three commercially available antigen tests varied between 92% and 98%, rendering  false 
positives unusual.72 Generally, positive test results confirm the infection, but weak false positive 
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can be obtained four to eight days after administration of attenuated live CPV vaccines in dogs.75 
Negative results may be confirmed by PCR methods.34,52 
3.4.2.2. Haemagglutination Testing  
Parvoviruses agglutinate erythrocytes, making it possible to detect the presence of virus 
in faecal samples.52 A haemagglutination protocol, which uses porcine erythrocytes, designated 
as slide agglutination test is described to indicate the presence of parvovirus strains in faecal and 
intestinal samples.76 Although they can be considered a rapid method for diagnosis, 
haemagglutination does not seem to overcome the limitation of traditional methods54, as it is 
considered to have similar sensitivity to ELISA and to be poorly specific, which can be related 
with the presence of isoagglutinins in faecal material, and as well other haemagglutinating 
viruses.34 
Furthermore, fresh erythrocytes are constantly required for this type of assay, causing 
problems related to the availability and management of porcine erythrocyte donors.54 Erythrocytes 
of other species (cat, rhesus monkey) can be used, however it may be difficult to obtain the 
required quantities and can increase the cost of the test.34 
3.4.2.3. Faecal Electron Microscopy 
As described for FPV detection, faecal electron microscopy is mostly used as a research 
tool, however is offered by some laboratories for the diagnosis of viral enteritis, when it is not 
possible to use antigen tests or PCR assays. Diagnosis of other viral agents, such as rotavirus 
and coronavirus may be facilitated by EM.34,54 
Nevertheless, the use of this tool is time-consuming for diagnosis proposes and requires 
technical expertise. Identification of parvovirus-like morphology can be poorly sensitive, and large 
amounts of virus must be present for positive results.52 
3.4.2.4. Virus Isolation 
It is possible to isolate every canine parvovirus variants using canine and feline cells. This 
requires the availability of cell cultures, and consequently virus isolation can be carried out only 
in specialized laboratories.70 Moreover, virus isolation can present low sensitivity, which is related 
with the intestinal lumen antibodies of infected animals that bind virions, preventing viral 
attachment to cell receptors. Furthermore, parvovirus strains may show minimal cytopathic 
effect.34 Turnaround time can be slow, as a long incubation period (five to ten days) is required 
and additional testing by haemagglutination or immunofluorescence may be needed to detect 
viral antigens.17 Thus, as for FPV, virus isolation is not commonly used for diagnosis, remaining 
an important research tool.59 
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3.4.2.5. Molecular Diagnosis 
For diagnosis proposes, PCR assays are valuable when faecal antigen ELISA tests are 
negative, but parvovirus infection is suspected.59 Although molecular methods can be time 
consuming, labour-intensive and require trained staff, because of the risk of carryover 
contaminations, especially with a high throughput of samples, PCR has been a reliable tool for 
diagnosis of CPV infection.52,54 
Since the 1990s, a nucleic acid hybridization assay is  available.77 Since then, different 
PCR assays were developed, increasing sensitivity and specificity to detect CPV in faeces of 
infected dogs. Thus, a rapid and not expensive method is generally used for DNA extraction, 
based on boiling faecal homogenates, however, due to the risk of faeces inhibiting the enzymes 
used in the assay, it is important to optimise extraction techniques and include controls, 
minimising possible false negative results.34,54 
The modified-live virus of the commercially available vaccines can be shed in the faeces, 
although at low titres and for a shorter time, when compared with field strains.75,78  In a clinical 
case of enteritis after vaccination, this situation could cause a false-positive result in conventional 
PCR, causing a misdiagnosis of the disease, which is probably caused by other enteric 
pathogens.52,59 Additionally, vaccine-induced disease due to reversion to virulence has been 
suggested but was never clearly demonstrated.54,75 
Real-time PCR allows a higher throughput, enabling simultaneous processing of several 
samples, as different steps are automatied.54,79 Another important advantage is the high 
sensitivity and reproducibility of the real-time PCR assay, providing an estimation of the viral DNA 
load, allowing the detection of virus-particles shed at low titres in faeces.79 Moreover, this has a 
particular impact in kennels and shelters, making it possible to adopt measures of prophylaxis to 
adequately prevent CPV infection, which is often responsible for epizootic scenarios. 
Furthermore, using real-time PCR, it is easily possible to specifically identify CPV variants 
circulating in the field and to distinguish field strains from vaccine strains.80 
3.4.2.6. Serological Testing  
CPV antibodies measurement can be done in the laboratory using HI. Additionally, ELISA 
assays are also available for semi-quantitative measurement of antibodies to CPV in-hospital.52,70 
However, serology is not the best method to confirm the infection, as most dogs are vaccinated 
against CPV or had previously contact with the virus. Therefore, these assays are often used to 
evaluate the MDA titres in pups, assessing the need for vaccination.54,59 ELISA test kits for semi-
quantitative IgG and IgM measurements and for determining adequate IgG titres for vaccination 
are commercially available.34,59 
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3.5. Pathological Findings 
 
A varied range of gross and histopathological findings are caused by parvoviruses, which 
can vary from minimal to severe. At necropsy, the most common finding is segmental enteritis 
(Fig. 4).22,59 
Early lesions are more common in the distal duodenum, progressing through the jejunum. 
The large intestine is rarely affected.52 The small intestinal wall is generally thickened and 
segmentally discoloured, with roughening or fibrin adhering on the serosa surfaces. Mucosa is 
often smooth and glassy. Lumen can contain watery to mucoid and bloody material. Gross lesions 
are usually classified as nonspecific enteritis.22,59 
The histological examination is generally definitive. As the disease progresses, loss of 
crypt architecture and necrosis of the crypt epithelium are often observed. The villi are shortened 
or obliterated, resulting in collapse of the lamina propria.52 A common finding, especially in acute 
cases, is intranuclear viral inclusion bodies in epithelial cells and throughout the squamous 
epithelia of the upper gastrointestinal tract.22 In chronic cases, intranuclear inclusion bodies are 
not often present, which correlates with decreased CPV antigen detection.22 Necrosis and 
depletion of the lymphoid tissue (Peyer’s patches, mesenteric lymph nodes, thymus, and spleen) 
are frequently observed.59 Secondary septicaemia is a common finding, and pulmonary oedema 
or alveolitis can be observed in these cases.52 
 
 
 
 
 
 
 
 
 
 
Figure 4. Intestine from a dog with acute parvovirus infection. There is segmental enteritis, 
with the affected segment on the left and the unaffected segment on the right. (Reproduced 
from Lamm C. et al., 200822) 
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Myocarditis is present especially in cases of younger animals, and is recognized grossly 
as pale streaks in the myocardium. The lesions are often classified as a non-suppurative 
myocarditis with multifocal infiltration of lymphocytes and plasma cells within the myocardium.22 
Basophilic intranuclear inclusion bodies are observed in cardiac muscle fibres and  parvovirus-
like virus particles in the inclusion bodies can be seen by EM and by in situ hybridization.22,59  
Specific identification of parvovirus in tissue specimens is achieved by 
immunofluorescence or other immunochemical methods.59 Because of the loss of detectable 
antigen, immunochemical methods can give false negative results in later stages. Moreover, 
quantitative PCR methods have been described as the most specific and sensitive tool for virus 
identification in tissue specimens, detecting more than 90% of infected animals.52 In fact, virus 
detection may be more prevalent in the tongue compared to other tissues, when there is autolysis 
or freezing and thawing before necropsy.52 
3.6. Therapy and Prognosis  
 
The therapy of parvovirus infection is supportive and symptomatic. The patient should be 
hospitalized in isolation.22 The primary goals of symptomatic treatment for parvoviral enteritis are 
restoration of fluid and electrolyte balance, and prevention of secondary bacterial infections.52 
Intravenous fluid therapy is indicated and should be continued for as long as vomiting or 
diarrhoea, or both, persists. A balanced electrolyte solution such as lactated Ringer's solution 
supplemented with potassium and 2.5% glucose is often used.81 
Single agent antimicrobial therapy with anaerobic coverage, such as metronidazole or 
ampicillin may be sufficient in many cases.82 However, in cases with haemorrhagic diarrhoea a 
combination of antimicrobial drugs is recommended.22 Thus, antimicrobial agents with activity 
against gram-negative and anaerobic bacteria are recommended in combination due to the 
severe disruption of the intestinal epithelium allowing bacteria into the blood stream and 
peripheral neutropenia increases the risk of sepsis.59 The most common bacteria appear to be 
Escherichia coli and C. perfringens.52,64 A common combination used is a penicillin and an 
aminoglycoside for gram-negative aerobic and anaerobic bacteria spectrum. The patient should 
be fully hydrated before aminoglycoside administration, because of their potential  
nephrotoxicity.59 
When nephrotoxicity of aminoglycosides is a concern, parenteral penicillin or third-
generation  cephalosporines may be used as alternatives to achieve the desired spectrum.59 The 
use of quinolones, which have a good gram-negative aerobic antibacterial spectrum, must be 
avoided in young growing animals, as it has been associated with cartilage damage in prolonged 
use.52,81 
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Anti-emetic drugs are needed to manage severe vomiting. Frequent or persistent 
vomiting can be managed with metoclopramide hydrochloride and prochlorperazine or 
administration of maropitant.81 The serotonin receptor antagonists are also described as 
efficacious anti-emetics. Both ondansetron and dolasetron have been used in dogs. However, the 
use of these anti-emetic agents does not always limit the vomiting, and their use should be closely 
monitored, because it can lead to hypotension.52 
Usually, oral intake may be suspended until vomiting has stopped for at least 24 hours, 
which could take up to three to five days in severe cases. It has been recommended, instead of 
avoiding the oral route completely, to trickle-feed small amounts of glutamine-containing solutions 
with the objective of reducing bacterial translocation.81 Also, when dogs with parvoviral enteritis 
were fed, starting on the first day of treatment via naso-oesophageal tube, their recovery time is 
shorter, and body weight was maintained, when compared to dogs treated with the conventional 
methods of food withholding until signs had ceased (12 hours).83 After vomiting is controlled, it is 
advised to introduce initially small amounts of a bland diet.59 
The loss of blood caused by parvovirus enteritis can lead to severe anaemia in some 
puppies. Transfusion of whole blood is of benefit in these cases. When hypoproteinaemia is 
present a whole blood transfusion will help, however, a plasma transfusion is more 
appropriate.52,62 Plasma can provide immunoglobulins and colloidal albumin, however antibody 
titres may not be sufficient to be beneficial, and the animal usually develops is own effective 
antibody response within three days after onset of clinical signs. Thus, hyperimmune plasma 
administration is described but has been questioned because, after the onset of clinical signs, the 
level of antibodies may be increased.52,59 The use of synthetic colloids such as hetastarch is 
described when oedema is present because of decreased proteins and is not corrected by plasma 
transfusion. Hetastarch has anticoagulant properties, which can be useful considering 
hypercoagulable states. However, their use remains controversial as it has been associated with 
acute kidney injury.59,84 
Glucocorticoids may be used to treat early sepsis or endotoxemia. However, their use 
should only happen when dehydration is correct and repeated doses are not advised.52 Other 
authors consider that the use of glucocorticoids is of unproven benefit in parvoviral enteritis 
secondary complications.81  
Other adjuvant therapies have been investigated, including anti-endotoxin sera, 
recombinant bactericidal permeability-increasing (BPI) protein85, recombinant granulocyte 
colony-stimulating factor (G-CSF)86 and oseltamivir.87 However, these therapies remain 
controversial as no significant difference in the clinical outcome was found and further 
investigation is required.59 In contrast, treatment of pups with recombinant feline interferon-omega 
(rfIFN-ω) has been associated with significantly reduction of disease severity and mortality.52,59,88 
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The prognosis may vary with the severity of illness and owners’ ability to afford 
appropriate treatment. It is described that pups that survive the first three to four days of parvoviral 
enteritis typically make a rapid recovery, up to 1 week in uncomplicated cases.52,59 Severe cases, 
which are characterized by development of secondary sepsis or other complications, require 
further hospitalization and aggressive treatment.59,89 Moreover, it is reported that with appropriate 
care, 75% of parvovirus cases should respond to medical therapy.22  
3.7. Immunity and Prevention  
 
The environment is the focus of concern to prevent the virus spreading. Disinfection 
procedures are as described for FPV. Additionally, as  parvoviruses are resistant to heat, surviving 
at 70ºC for 30 minutes, steam cleaning can be used on surfaces that do not tolerate 
hypochlorite.41,52 
In shelters, quarantine periods of two weeks are recommended  to pups that might be 
shedding the virus.41 Rodent and insect vector control is recommended to prevent dissemination 
of virus in the environment.59 The regular removal of faecal contamination and minimization of 
possible stressors, such as overcrowding, poor nutrition, and parasitism can also help to decrease 
the prevalence and impact of enteric viral infections, such as the parvoviral enteritis.41,52 
Vaccination is widely available and is the most effective method to prevent the CPV 
infection in dogs. Both live attenuated and inactivated vaccines are available.52,59 However, 
commercially inactivated CPV vaccines have been extensively replaced by live attenuated 
vaccines, which provide superior and longer duration immunity. Without the interference of MDAs, 
the protection against CPV infection is as early as three days post-vaccination.90 MLV CPV 
vaccines replicate in the intestinal tract and lower quantities of virus are shed after vaccination, 
usually up to 10 days. However, a recent study demonstrated faecal shedding up to 28 days after 
vaccination.75,78 Although concerns about the possible reversion of virulence which could cause 
apparent disease have been raised, different studies have shown that attenuated live vaccines 
are safe.52,54,91 
Maternal antibody interference and the lack of sufficient seroconversion response are the 
primary causes of vaccination failure.54 The window of susceptibility is the period when MDA 
interferes with the ability of the vaccine to stimulate an effective immune response, but does not 
prevent infection with virulent wild-type virus.59 The window of susceptibility was reported to be 
between the age of 40 to 69 days; however, this may vary.92 
Serological tests to determinate MDAs titres can help to predict the age at which a pup 
should be vaccinated successfully. Nevertheless, this could represent an extra-cost in the 
vaccination approach.54 Several strategies have been proposed to overcome MDA interference, 
such as high-titre vaccines and intranasal vaccination. Nowadays, the WSAVA Vaccination 
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Guidelines Group recommends delaying the primary CPV vaccination course to 14-16 weeks of 
age, with the aim of ensuring effective immunization even in pups with long-lasting MDA.49,52,54 
Therefore, pups of unknown immune status are usually vaccinated initially at six to eight 
weeks of age, with three to four weeks interval, continuing through to 14 to 16 weeks of age (16 
to 20 weeks in breeding kennels).52 At 1 year of age, a booster should be given, repeating every 
3 years. In Europe, multivalent vaccination is often used, which is known as DHPPi, providing 
immunity against canine distemper, canine parvovirus, canine adenoviruses, and canine 
parainfluenza.49 To confirm the protection against CPV, serum antibody titres of at least 1:80 are 
well correlated with protection after vaccination.90,93  
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4. Epidemiological Evolution of Canine and Feline Parvoviruses 
4.1. Host Range and Evolution Perspective 
 
Feline panleukopenia-like disease was recognized in cats more than 100 years ago22, 
and was first reported in the literature in 192816. The virus has remained stable, with minor 
variations in its genome.18 Moreover, it is not only able to cause significant disease in domestic 
cats, but also infect an extensive variety of wild felids and other wild carnivores. Until the late 
1970s, domestic dogs and close relatives, such as wolves and coyotes, were resistant to FPV-
like virus infection.7 
In 1978, a new virus variant emerged infecting domestic dogs, causing a pandemic 
disease and spreading worldwide in the late 1970s, being also able to infect wildlife species, such 
as coyotes and raccoons. This virus was identified as CPV-2, distinguishing the virus from the 
distantly-related minute virus of canines (MVC), also known as CPV type 1 (CPV-1).55,56 
Phylogenetic analysis has shown that CPV-2 was derived from a common ancestor, shared with 
FPV and other parvoviruses such as raccoon parvovirus (RPV) and blue fox parvovirus 
(BFPV).7,58  
As previously mentioned, although CPV and FPV are around 98% identical in DNA 
sequence, they have specific host ranges and antigenic properties that are controlled by the 
capsid protein gene.58 The new canine host range of CPV-2 can be explained by a small number 
of mutations in the capsid protein gene, which altered residues in the surface of the capsid, and 
it is believed that wild animals, such as raccoons and foxes, are associated with the viral evolution. 
The capsid uses the transferrin receptor (TfR) type-1 to bind and enter the cells for infection, and 
the residues on the surface of the capsid controls the interaction with the TfR.12 Thus, as the FPV 
is unable to bind canine TfR, the specific host range for dogs is related to a few amino-acid 
changes, which allow effective binding by the virus. This successful viral adaption involved six 
genomic changes associated with the threefold spike of the capsid, allowing CPV-2 to infect the 
canine host range, but losing the ability to replicate in cats.57 
Therefore, the changes at VP2 residues 93 (Lys to Asn), 103 (Val to Ala) and 323 (Asp 
to Asn) between FPV and CPV-2 explain the acquisition of the canine host and range, whereas 
the differences of VP2 residues 80 (Lys to Arg), 564 (Asn to Ser) and 568 (Ala to Gly) can explain 
the loss of the feline host range. Other changes at the residues 232 (Val to Ile) and 375 (Asp to 
Asn) were found in some isolates of the original strain of CPV-2, however it is suggested that 
these variations are not critical to the success of CPV-2 in nature.19,57 
In the early 1980s, CPV-2 was replaced by a genetic and antigenic variant, named CPV-
2a, which spread worldwide within a period of three years, suggesting that CPV-2a had an 
epidemiological advantage over CPV-2.94 In fact, CPV-2a had reacquired the ability to infect cats, 
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becoming the dominant lineage of the virus (Fig. 5). The variation in the residues 87 (Met to Leu), 
300 (Ala to Gly) and 305 (Asp to Tyr) allowed the replication in cats, and other changes on the 
residues 101 (Ile to Thr), 297 (Ser to Ala) and 555 (Val to Ile) are described between the original 
CPV-2 and CPV-2a viruses.57 
In 1984, only a few years after the original CPV-2 emerged, another antigenic variant was 
detected in the United States of America (USA), named CPV-2b with a change at residue 426 
(Asn to Asp), and in the VP2 residue 555 (Ile to Val). However, only the difference at residue 426 
is antigenically significant.19,57 
 
 
In 2000, a CPV-2c variant was reported in Italy95, however CPV-2c was found in archived 
samples from 1996, in Germany, revealing that this strain was circulating in Europe before the 
first reported case in Italy.96 CPV-2c strains have an antigenic change in the same residue as 
CPV-2b. Thus, antigenic differences between the 3 variants are presented at residue 426 – Asn 
in CPV-2a, Asp in CPV-2b and Glu in CPV-2c – affecting the major antigenic region, located at 
the threefold spike in the VP2 protein (Table 1). While some authors disagree with the strain 
nomenclature, due to the strains differing only at one position, and other designations were 
proposed recently, the reference to CPV stains 2a, 2b and 2c is prevalent in the literature.6,57,97 
Other VP2 mutations were reported in the antigenic variants and include the amino acid 
change at VP2 position 297 (Ser to Ala) both in CPV-2a and 2b. These variants have been also 
designated as New CPV-2a and 2b.57,98 The 300Asp variation, of CPV-2a and 2b has been 
reported more recently, and may be related to extended adaptation of the virus in the feline or 
raccoon hosts.13,99  In fact, although CPV is a DNA virus, its genomic substitution rate is about 
10-4  per site per year, which is comparable to RNA viruses.6,100 
The three antigenic variants of CPV-2 are distributed worldwide, being able to infect a 
variety of different hosts. Thus, the emergence of the CPV-2 strains and reacquiring the capacity 
to replicate in the feline host, represent a selective advantage for the virus.57 
 
 
Figure 5. Feline and canine parvoviruses host range evolution. 
(Reproduced from Miranda C. et al., 2016 57) 
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4.2. Canine Parvovirus Infection in Cats 
 
As previously described, CPV-2 variants can induce disease in infected cats, with clinical 
signs indistinguishable from feline panleukopenia. However, the natural infection is often 
asymptomatic.101 Thus, the onset of clinical illness may be associated with the general condition 
of the affected cats at the time of  exposure.23 
Milder clinical signs were associated with CPV-2a or CPV-2b infection in cats, when 
compared to those with FPV infection, suggesting that CPV-2 variants were less virulent in cats.102 
However, several reports of CPV-2c isolated from cats claim that this strain is most pathogenic to 
felids.37,103 
Similar to the common alterations in dogs, pronounced lymphopenia and mild leukopenia 
are often described in cats infected with CPV-2 strains.17 These findings frequently contrast to the 
marked leukopenia and mild lymphopenia found in cats with FPV infection.22 
Parvoviral infection can be clinically diagnosed using the tests already described for FPV 
infection in cats and CPV infection in dogs, however, none of the routine clinical tests can 
accurately distinguish FPV from CPV-2 variants. Thus, to distinguish FPV and CPV-2 isolates, HI 
with specific monoclonal antibodies, sequence analysis of sizable portions of the VP2 gene, or 
the use of Minor Groove Binder (MGB) probes in quantitative PCR, which uses different 
fluorophores to detect Single Nucleotide Polymorphisms (SNPs) existing between the CPV-2 
strains, is recommended (Table 1).38,54 
Therapy should be the same as described for treating feline panleukopenia. Preventive 
measures, including vaccination, are the same described for feline panleukopenia infections, as 
it has been reported that attenuated FPV vaccines are able to elicit protection in domestic cats 
against FPV and CPV strains.50,104 However, the cross-reactivity of FPV vaccines against CPV-2 
strains has been under discussion.
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Aa Residue 80 87 93 101 (b) 103 232 297 300 305 323 375 426 (c) 555 564 568 
Nt (d) 
position 
3024-3026 3045-3047 3063-3065 3087-3089 3093-3095 3480-3482 3675-3677 3684-3686 3699-3701 3753-3755 3909-3911 4062-4064 4449-4451 4476-4478 4488-4490 
Codon 
observed 
AAA (Lys) 
AGA (Arg) 
ATG (Met) 
TTG (Leu) 
AAA (Lys) 
AAC (Asn) 
AAT (Asn) 
ATT (Ile) 
ACT (Thr) 
GUA (Val) 
GCA (Ala) 
GTA (Val) 
ATA (Ile) 
TCT (Ser) 
GCT (Ala) 
GCT (Ala) 
GGT (Gly) 
GAT (Asp) 
TAT (Tyr) 
GAC (Asp) 
AAC (Asn) 
AAT (Asn) 
GAT (Asp) 
AAT (Asn) 
GAT (Asp) 
GAA (Glu) 
GTA (Val) 
ATA (Ile) 
AAT (Asn) 
AGT (Ser) 
GCT (Ala) 
GGT (Gly) 
FPV Lys Met Lys Ile Val Val Ser Ala Asp Asp Asp Asn Val Asn Ala 
CPV-2 Arg Met Asn Ile Ala Ile Ser Ala Asp Asn Asn Asn Val Ser Gly 
CPV-2a Arg Met Asn Thr Ala Ile Ser Gly Tyr Asn Asp Asn Ile Ser Gly 
CPV-2b Arg Leu Asn Thr Ala Ile Ser Gly Tyr Asn Asp Asp Val Ser Gly 
New CPV-2a Arg Leu Asn Thr Ala Ile Ala Gly Tyr Asn Asp Asn Val Ser Gly 
New CPV-2b Arg Leu Asn Thr Ala Ile Ala Gly Tyr Asn Asp Asp Val Ser Gly 
Asp-300 
(2a/2b) 
Arg Leu Asn Thr Ala Ile Ala Asp Tyr Asn Asp Asn (2a) 
Asp (2b) 
Val Ser Gly 
CPV-2c Arg Leu Asn Thr Ala Ile Ala Gly Tyr Asn Asp Glu Val Ser Gly 
Table 1 footnotes: 
(a) Positions are referred to the amino acid and nucleotide sequences of strain CPV-b (GenBank accession no. M38245) 
(b) Codon affected by SNPs used to design type-specific probes distinguishing CPV-2 from CPV-2a/2b/2c 
(c) Codon affected by SNPs used to design type-specific probes distinguishing CPV-2a from CPV-2b, and CPV-2b from CPV-2c 
(d) Nucleotide (Nt) 
 
Table 1. Amino acid variations in the VP2 protein of feline and canine parvoviruses (a). (Reproduced from Decaro N. et al., 2012 54) 
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4.3. Vaccination Efficacy: heterologous strain protection challenge 
 
Concerns about the efficacy of CPV type 2-based vaccines against the antigenic variants 
have been raised,  as many  commercially modified live virus vaccines are  based on the original 
type CPV-2, which was isolated in the early 1980’s.90,105 Although cross-protection against the 
different strains was shown, generally, vaccines should contain the newest antigenic types of a 
given virus, implying the most complete possible protection.105 Consequently, different studies 
were conducted to address this topic. 
On one side, CPV-2 vaccines were shown  to induce immunity against the homologous 
(vaccine) virus, but presented significantly lower cross-reactivity with its variants, which 
presumably can allow infection of these strains in vaccinated dogs.54,106,107 Thus, the divergence 
between the vaccine and field strains can contribute to increase the risk of an outbreak in the 
canine population.108 
Moreover, in most CPV-2c outbreaks involving adult dogs, the vaccination schedules 
were completed, including a yearly booster vaccination.54,109,110 In young dogs, it is also described 
that they have undergone the vaccination protocol within the first year of life.54,111,112 Regardless 
of these reports, different studies have demonstrated that type-2 vaccines are able to protect dogs 
against the CPV-2c challenge, under experimental conditions.54,91 However, there is a lack of 
information regarding the immunity elicited by the original CPV-2 vaccines against the 2c strain 
after an extended interval between vaccination and challenge, when the type-2 antibody titres 
could be lower than necessary to prevent infection and disease caused by strains circulating in 
the field.54,113  
Considering the concerns about the antigenic differences between the original CPV-2 
strain and the field strains, which may decrease the effectiveness of vaccination, a wider use of 
vaccines type 2b-based has been suggested.54,106,112 
Recently, studies conducted by a vaccine manufacturer have demonstrated that a recent 
multivalent vaccine containing a CPV-2b strain was able to induce cross-neutralising antibody 
responses to CPV strains, and can protect against a virulent CPV-2c infection in dogs.91,114  
The emergence of the CPV-2 variants in cats causes the same concerns about the 
effective efficacy of the traditional FPV-based vaccines against the infections of the strains 2a, 2b 
and 2c in the feline population.46 It has been reported that a common FPV-based vaccine was 
able to elicit cross-protection against CPV-2b, however, antibody titres against these CPV strains 
were significantly lower, when compared to FPV-antibodies. Additionally, it has been reported 
that the CPV-2c strain had the lowest degree of cross-protection, which could explain the higher 
degree of virulence of this variant in cats.46,54 Recently, a study conducted by a vaccine 
manufacturer has shown that a multivalent vaccine was able to protect cats against infection and 
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associated lymphocytopenia following challenge with CPV-2b and 2c, under experimental 
conditions, up to 20 days post-infection.50 However, further studies are needed to address this 
question and multivalent vaccines containing FPV combined with a CPV strain variant should be 
considered, the CPV-2c strain being a logical candidate for the vaccine antigen, to offer cross-
immunity in field conditions.23,37 
Despite the distinct positions described about this topic, it is important to highlight that 
continuous surveillance studies should be done, allowing the record of distribution of CPV-2 
strains and assessment of vaccine efficacy in both canine and feline populations.18,113,115 In 
addition, a recent study reinforces the need to develop specifically-designed clinical trials, which 
should include adequate size sample and follow-up, to obtain reliable information about the cross-
protection from currently licensed vaccines.108 
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4.4. Worldwide distribution of Canine Parvovirus variants 
 
In late 1970s and early 1980s, the early evolutionary events of CPV-2 were characterized 
by global dissemination and replacement by CPV-2a. After the emergence of CPV-2b and CPV-
2c, it was reported that all the CPV strains were globally distributed in the canine population. The 
prevalence of CPV-2 strains may vary, depending on geographical region (Fig. 6).57 
Therefore, epidemiological reports shown that CPV-2a is predominant in Australia, most 
of Asian countries and Europe, and is the only variant reported in New Zealand, Nigeria and some 
Eastern European countries.96,116,117 However, CPV-2b prevalence has been reported in several 
countries within the five continents, being the predominant strain in Ireland, UK, USA and in a few 
countries of Asia. Other reports have shown that CPV-2a and 2b were equally distributed in 
Belgium, Switzerland and Austria. In addition, the CPV-2c has been mainly found in South 
American and European countries.57,96 
 
In addition, the prevalence of the different CPV-2 strains may also vary across different 
regions of the same country where the samples are collected, as was reported in Portugal, where 
in the continental south and the island regions, CPV-2c was reported to be the predominant strain, 
in contrast with the north and central continental region, CPV-2b was reported to be the prevalent 
variant.118,119 
Figure 6. Geographical distribution of three CPV variants based on 426 residue detected 
in dogs population worldwide.  
Footnotes: Orange: presence of three CPV variants; green: presence of two of three CPV 
variants; yellow: presence of one of three CPV variants. (Reproduced from Miranda C. et al., 
2016 57) 
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The prevalence of CPV infection in clinically-healthy cats or in cats with panleukopenia 
remains unknown, however the isolation of CPV-2 variants has been reported worldwide.57 In one 
study in Vietnam and Taiwan more than 80% of the isolates from cats with panleukopenia were 
types of CPV.99 In Germany, one study found that around 10% of viruses isolated from cats with 
panleukopenia were CPV-2a or a CPV-2a-derived variant.19,120 Several studies reported the 
isolation of CPV-2a and 2b in domestic cats from Europe, Japan, to India.37,121,122 CPV-2c was 
also been detected in clinically ill cats103,123, and as well in co-infections by multiple CPV variants, 
and mixed infections with FPV and CPV-2 strains.26,124 
The frequency of distribution of the CPV strains has shown differences associated with 
the year of collection of samples. Moreover, the reasons behind the differences found in the world 
distribution of CPV-2 variants are not completely understood, which is associated with the genetic 
diversity and its dynamic changes during the CPV evolution, suggesting that field parvoviruses 
are under strong selection pressure.54,57 
Therefore, the three CPV-2 strains are circulating worldwide, being difficult to state which 
variant is predominant. In addition, the geographical variation in CPV distribution highlights the 
importance of surveillance reports, providing more data to the study of the parvovirus 
epidemiology.54,113,115 
 
4.5. Epidemiological Surveillance in the United Kingdom  
 
Disease surveillance has been described as the ongoing systematic collection and 
analysis of data to characterize the current health and disease situation within a given population. 
In the UK, disease surveillance has been a standard practice in farmed livestock and equine 
populations.125 However, and despite the estimated UK population of 11.6 million dogs and 10.1 
million cats in 2011, disease surveillance of the UK small companion animal population has been 
lacking.125,126 
Although vaccination is widely available, clinical illness due to CPV infection is still a 
common finding by veterinary practices across the UK. In fact, accordingly to the Small Animal 
Veterinary Surveillance Network (SAVSNET), which has the aim of collecting data from veterinary 
practices across the UK, to increase the understanding of current disease burden in small 
companion animal population, a mean percentage of 13.2% of samples testing positive for CPV-
2 strains was found by laboratory-based surveillance of submitted samples from dogs, between 
October 2013 and September 2014, and a mean percentage of 10.7% of positive samples for 
CPV-2 variants was reported between October 2014 and September 2015.125 
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In 2008, a study using samples from clinically-ill dogs was conducted with the objective 
of determining which strains of CPV were circulating in the UK. It was found that CPV-2b was the 
most prevalent strain, followed by CPV-2a; no CPV-2c was found in this study.127 The CPV-2b 
strain was the most prevalent strain in a previous study using UK samples, which found only one 
CPV-2c isolate in the country.96 In another study, a significant geographic clustering in some 
areas was found, suggesting that CPV-2a and 2b may have different distributions across different 
areas of the UK.128 
Additionally, the prevalence of parvoviruses in clinically-healthy cats and dogs was 
investigated in two rescue shelters in the UK. A prevalence of 32.5% of CPV-2 strains, in faeces, 
was found in a cross-sectional study of 50 cats from a feline-only shelter. Also, 33.9% of cat faecal 
samples tested positive in a longitudinal study of 74 cats from a mixed canine and feline shelter. 
Randomly selected positive samples were identified as CPV-2a or 2b.101 
Longitudinal sampling of the mixed shelter, showed that all cats shed the same virus 
strain at each date they were positive, despite the lack of clinical signs. Although many cats were 
shedding CPV-2 strains, canine faecal samples from this shelter were negative for CPV-2 
variants. In addition, half of the sequences of the feline strains were similar to those obtained from 
a previous study of clinically-affected dogs in the UK.101,128 
Therefore, it was shown that clinically healthy cats can shed CPV for prolonged periods 
of time, suggesting that cats can represent an important reservoir for the maintenance of infection 
in both cat and dog population.101 For that reason, it is important to continue to conduct 
surveillance studies, providing information on what extend is parvovirus circulating in the UK and 
what antigenic variants are found in the field. 
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II. Research Project 
5. Aim 
 
A previous study from 2007 has reported CPV-2a and CPV-2b isolated from dogs in the 
UK, and only one CPV-2c isolate from the same population.96 Subsequently to this study, in 2008, 
CPV-2a and CPV-2b strains were identified in a clinically-ill dog population.127 In 2011, another 
report shared the same findings on the CPV-2 variants in the UK.128 In all these studies, CPV-2b 
was the most prevalent strain reported. Therefore, to date, only one CPV-2c isolate from dogs 
was reported, and no CPV-2c was previously detected in cats in the UK.  
No study has been documented in the UK to determine the circulating variants of 
parvoviruses in asymptomatic cats since 2012.101 It would be interesting to know to what extent 
currently-circulating CPV variants infect cats. 
The aim of this study was to investigate the prevalence of feline and canine parvoviruses 
infection in cats, and to genetically characterise possible positive samples, generating data on 
the molecular surveillance of parvoviruses circulating in a non-clinical cat population in the UK. 
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6. Materials and Methods  
6.1. Sample Collection and Study Population 
 
The samples used in this project were kindly made available by Dr. Allison German and 
Prof. Kenton Morgan, from the Institute of Infection and Global Health, University of Liverpool, 
and resulted from a study on  molecular epidemiology of rotavirus in cats in the UK.129 
The collection included a total of 1,727 faecal samples, from a total of 25 adoption centres 
in the UK run by Cats Protection, the largest feline welfare charity in the UK. The samples were 
collected during the winter and summer months of 2012.129 
Shelters are widely distributed geographically in the UK, and vary in size and construction. 
The number of cat accommodation spaces ranges from 16 to 202 per centre, and the populations 
of cats are in constant flux.129 
The 818 faecal samples of this cross-sectional study were collected in 2012 from cats 
held in 13 adoption centres across the UK (Figure 7), and originally part of a larger biobank of 
1,727 samples.  
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Map Legend: 
1. York 
2. St Helens 
3. Mansfield 
4. Birmingham 
5. Downham Market 
6. Dereham 
7. Hereford 
8. Bridgend 
9. Truro 
10. Exeter 
11. Ferndown  
12. Isle of Wight 
13. Haslemere 
 
 
Figure 7. Geographical location of the cat rehoming centres (n=13). Map generated with ArcGIS™ (Esri®). 
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6.2. Sample Preparation and DNA Extraction 
 
Each faecal sample was maintained at -80ºC in the Biobank at the University of 
Nottingham’s School of Veterinary Medicine and Science until testing. An inventory was 
constructed with an alphanumeric code that was assigned to each box of samples during entry 
into the Biobank, the number of samples in each box, the shelter location and the individual 
numeric code of each sample.  
Template DNA from the faecal samples was prepared by adding approximately 1g of 
faecal material to a universal faecal sample tube containing 5ml of a 25% weight/volume mix of 
kaolin (Sigma-Aldrich) and 0.01M dithiothreitol (DTT) (Sigma-Aldrich) in Phosphate Buffered 
Saline (PBS). The preparation was thoroughly mixed for several minutes using a vortex. The tube 
was placed in a water bath at 37ºC for 15 minutes.  
Subsequently, 1.5ml of mixture from each tube was taken into a labelled microfuge tube 
by pipetting twice 0.75ml. The tubes were then centrifuged at 1300rpm for 5 minutes. Each batch 
of DNA extractions performed up to 48 samples. 
A volume of 5 µl of each sample supernatant was added to a labelled conical-bottomed 
1ml tubes containing 95 µl of diethyl pyrocarbonate (DEPC) treated water. The tubes were then 
boiled at 100ºC in a water bath for 10 minutes. 
After the DNA extraction steps were completed, the products of the DNA extraction were 
kept in the 1ml tubes labelled with an individual serial number, matching with the inventory, and 
were stored in plastic boxes, labelled with the box code, extraction serial number and date. 
6.3. Amplification by PCR 
 
To plan each PCR assay in 96-well plates, a MS Excel® (Microsoft®) spreadsheet with 
the plate layout was prepared before the PCR assay. Each PCR had an individual code, and each 
assigned well number corresponded to the individual numeric code from the sample and 
extraction number, as in the example presented in the Tables 2 and 3. 
To ensure PCR reliability, a negative control consisting of a master mix of the PCR 
template was separately prepared, made up with the volume for a 96-well plate, to run with each   
plate. Subsequently, the DNA template was separately and carefully added to each well. The 
components of each PCR reaction are described in Table 4. The DNA polymerase used was the 
MyFi™ DNA polymerase (Bioline®), which has higher fidelity than native Taq polymerase, 
accordingly to the manufacturer. The MyFi™ reaction buffer contains 1 mM dNTPs, 3 mM MgCl2, 
DNA polymerase and enhancers, which means that it was not necessary to add these 
components separately, when preparing the PCR master mix.  
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Primers (Sigma-Aldrich®) were designed by Dr. Stephen Dunham to allow both FPV and 
CPV detection (Table 5), spanning the amino acid 426 region of the VP2 gene, which determines 
the CPV-2 variants. The product size of the reaction was 428 base pairs (bp).  
The PCR cycling conditions were defined as follows: initial denaturation at 95ºC for 1 
minute; 40 cycles of: denaturation of 15 seconds at 95ºC, followed by a primer annealing at 60ºC 
for 15 seconds; extension at 72ºC for 15 seconds; and a final extension of 2 minutes at 72ºC. A 
Life ECO™ thermal cycle (Bioer®) was used to run the reactions. 
Master mix contains Per tube (µl) 
DEPC treated water 9.0 
MyFi polymerase mix 12.5 
Forward primer (felVP2-3820) 0.5 
Reverse Primer (VP2-4247R) 0.5 
DNA Sample 2.5 
Total 25.0 
Table 4. PCR master mix contents per reaction tube. 
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Row/Column 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 
A 89 81 73 65 57 49 41 33 25 17 9 1 (JD11a) 
B 90 82 74 66 58 50 42 34 26 18 10 2b 
C 91 83 75 67 59 51 43 35 27 19 11 3 
D 92 84 76 68 60 52 44 36 28 20 12 4 
E 93 85 77 69 61 53 45 37 29 21 13 5 
F 94 86 78 70 62 54 46 38 30 22 14 6 
G 95 87 79 (JD12a) 71 63 55 47 39 31 23 15 7 
H Neg Controlc 88 80 72 64 56 48 40 32 24 16 8 
 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 
A 26339013_11 26339003_3 22696076_73 22696065_65 22696057_57 22696049_49 22696041_41 22696033_33 22696025_25 22696017_17 22696009_9 22696001a_1b 
B 26339014_12 26339004_4 22696077_74 22696066_66 22696058_58 22696050_50 22696042_42 22696034_34 22696026_26 22696018_18 22696010_10 22696002_2 
C 26339015_13 26339005_5 22696078_75 22696067_67 22696059_59 22696051_51 22696043_43 22696035_35 22696027_27 22696019_19 22696011_11 22696003_3 
D 26339018_14 26339006_6 22696079_76 22696068_68 22696060_60 22696052_52 22696044_44 22696036_36 22696028_28 22696020_20 22696012_12 22696004_4 
E 26339019_15 26339008_7 22696080_77 22696069_69 22696061_61 22696053_53 22696045_45 22696037_37 22696029_29 22696021_21 22696013_13 22696005_5 
F 26339020_16 26339010_8 22696081_78 22696070_70 22696062_62 22696054_54 22696046_46 22696038_38 22696030_30 22696022_22 22696014_14 22696006_6 
G 26339021_17 26339011_9 26339001_1 22696071_71 22696063_63 22696055_55 22696047_47 22696039_39 22696031_31 22696023_23 22696015_15 22696007_7 
H Neg Controlc 26339012_10 26339002_2 22696075_72 22696064_64 22696056_56 22696048_48 22696040_40 22696032_32 22696024_24 22696016_16 22696008_8 
Table 2. Example of 96-well PCR plate layout planning (PCR individual code: P8.15.02.) 
Table 2 footnotes: (a) alphanumeric code of biobank box of samples; (b) number assigned per each well; (c) negative control. 
Table 3. Example of the 96-well PCR plate layout for the assay P8.15.02. 
Table 3 footnotes: (a) individual numeric code of the sample; (b) DNA extraction serial number; (c) negative control. 
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Each PCR plate had a negative control in one of the wells. An aliquot of the master mix 
was frozen down at -20ºC and was used to run a positive control in a separate reaction (to avoid 
cross-contamination).  
 
 
 
6.4. Agarose gel electrophoresis 
 
Tris-Borate-EDTA (TBE) 1x was used to prepare a 1.5% TBE agarose gel with Nancy-
520 fluorescent stain (Sigma-Aldrich®). TBE 1x buffer was also used in the electrophoresis tank. 
Each PCR product was prepared with 2 µl of gel loading dye (New England Biolabs®), 
making up a total volume of 6 µl. The agarose gel was usually prepared with 48-wells; a volume 
of 6 µl of 1Kb DNA ladder (HyperLadder™; Bioline®) was added to the first well and the PCR 
negative control to the last well. A positive control was run separately from the gel of the samples 
at the same time, to avoid cross-contamination. 
The gel electrophoresis ran for one hour and 30 minutes at 80V. The result of each 
electrophoresis was visualised under UV illumination using a gel imaging system (ImageQuant™ 
300; GE Healthcare®). 
6.5. DNA Sequencing  
 
Following gel electrophoresis, 10 positive PCR products (25 µl) were purified using 
QIAquick® PCR Purification Kit (QIAGEN), according to the manufacturer’s instructions. 
The DNA was then quantified using NanoDrop™ 2000 spectrometer (Thermo 
Scientific™), obtaining the concentration of DNA (ng/µl). The purified DNA products were sent for 
the Sanger Sequencing Service of the Source BioScience laboratories, along with the reverse 
primer VP2-4247R. Source BioScience laboratories required a concentration of 10 ng/µl for 
purified PCR samples and 3.2 pmol/µl for the primer sent, with a volume of 5 µl per reaction. 
 
 
Primer (a) Name Tm (ºC) Sequence (5´- 3´) 
Forward felVP2-3820F 62.8 TTGARGCRTCTACACAAGGG  
Reverse VP2-4247R 66.7 TGGTGCATTTACATGAAGTCTTGG 
Table 5. Primers used accordingly. 
Table 5 footnotes: (a) Primers (Sigma-Aldrich®) designed by Dr. Stephen Dunham. 
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6.6. Sequence analysis  
 
FinchTV™ software (Geospiza®) was used to visualize and obtain sequencing results. 
The reverse complement of the nucleotide sequences was obtained using a reverse complement 
tool available online (http://reverse-complement.com/), according to the fact that the reverse 
primer was used for sequencing.  
Sequences were then compiled into a MS Word® document with a reference sequence 
of CPV-2 (GenBank accession number: M38245) at the start, followed by the nucleotide sequence 
of each sample. 
The sequences were aligned using the multiple sequence alignment tool Clustal Omega© 
(EMBL-EBI) available online (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
6.7. Statistical analysis 
 
Prevalence is defined as the proportion of a population affected by instances of disease 
or related attributes, such as infection, at a given point in time. It can be interpreted as the 
probability of an individual from the same population having the disease at this given point in time. 
Although prevalence can be defined simply as the number of affected animals, it is most 
meaningful when expressed in terms of the number of diseased animals in relation to the number 
of animals in the population at risk of developing the disease.130,131 Accordingly: 
 
Prevalence131 = 
number of individuals infected
number of individuals in the population at risk
 
 
A 95% confidence interval (CI) was calculated using the QuickCalcs® tool (GraphPad® 
Software). 
 
 
 
 
  
43 
 
7. Results  
7.1. Gel Electrophoresis Results 
 
 From the total of 818 faecal samples extracted and PCR-screened for FPV and CPV 
infection, 31 were PCR-positive. All the specific electrophoresis bands were expected to have 
428bp, thus specific bands matching with the 400bp ladder were considered positive (Fig. 8). The 
HyperLadder™ 1kb weight marker scale is shown in the Figure 9. 
 
 
 
 
 
Figure 8. Example of a PCR-positive product in the electrophoresis gel, visualized under UV 
light. Visualization and image captured using ImageQuant™ 300 system; GE Healthcare®. 
 
Footnotes: 1 – HyperLadder™ 1kb (Bioline®); 2 – PCR-positive product. 
1 
2 
Figure 9. HyperLadder™ 1kb run on a 1% TBE-agarose gel and 
visualized using ethidium bromide. (Source: Bioline®, available 
at https://www.bioline.com/sg/hyperladder-1kb.html#RL) 
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Furthermore, some electrophoresis bands did not show high intensity under UV light, 
albeit specific (approximately 400bp). For that reason, fainter specific bands were considered as 
positive PCR-products (Fig. 10).  
The positive samples were distributed by Centre location and identification (ID) as 
presented in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Example of a specific positive faint band in the electrophoresis gel, 
visualized under UV light. Visualization and image captured using 
ImageQuant™ 300 system; GE Healthcare®. 
Footnotes: 1 – HyperLadder™ 1kb (Bioline®); 2 – PCR-positive band. 
1 
2 
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Centre and Sample ID Sample Purified (SP) No. Total of Positive Samples 
per Centre 
York 
 
1 
13476035 1  
Dereham 
 
15 
12166002 2  
12166017 3  
12166025 4  
12166032 5  
12166033 6  
12166038 7  
12166043 8  
12166044 9  
12166052 10  
12166054 11  
12166058 12  
12166059 13  
12166060 14  
12166069 15  
12166073 16  
Birmingham 
 
4 
6817004 17  
6817012 18  
6817039 19  
6817061 20  
Hereford 
 
2 
35179027 21  
35176006 22  
Truro 
 
1 
14076015 23  
Haslemere  1 
24736009 24  
Bridgend 
 
2 
6847095 25  
6847099 26  
Isle of Wight 
 
1 
6836050 27  
Downham Market 
 
3 
22696004 28  
22696009 29  
22696081 30  
Exeter  1 
26339006 31  
Total  31 
Table 6. Positive samples ID distributed by Centre, with an assigned positive number (n=31). 
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7.2. Genetic Sequencing Results 
 
Sequencing results of ten positive samples were sent by Source Bioscience, and were 
then visualized using FinchTV™. An example of a good sequence trace is shown in Figure 11, 
with little baseline interference (baseline “noise”). 
 
Other sequence products did not work so well, producing traces with high baseline 
interference, with multiple peaks at a given nucleotide position (Fig. 12). Thus, due to the low 
confidence in determining the right nucleotides and the presence of unreadable bases, the 
sequence traces that presented this condition were excluded from the analysis.  
 
Figure 11. Section of a good sequence chromatogram, with little baseline 
interference. (Visualized with FinchTV™; Geospiza®) 
Figure 12. Section of a sequence chromatogram with high baseline interference, 
presenting multiple peaks at a given nucleotide position. (Visualized with FinchTV™; 
Geospiza®) 
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After the reverse complement for each valid nucleotide sequence, a multiple alignment 
along with a reference sequence for CPV-2 (GenBank accession number: M38245) was done 
and it is presented in Figure 13. The sequence analysis considered the Nt position 4062-4064, 
which is the codon of the amino acid residue 426 (Table 1), spanned by the PCR assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SP26       GAGAAACACCCTCCAGATGGNTATG-TNGGTAGCATCACATNCAGGAAGATATCCGGAGG  
SP20       GAGAAACACCTGAGAGATTTATATATATAGCACATCAAGATACAGGGAGATATCCAGAAG  
SP18       GAGAAACACNTGAGAGATTTACATATATAGCACATCAAGATACAGGAAGATATCCAGAAG  
SP1        GAGAAACACCTGAGAGATTTACATATATAGCACATCAAGATACAGGAAGATATCCAGAAG  
SP12       GAGAAACACCTGAGAGATTTACATATATAGCACATCAAGATACAGGAAGATATCCAGAAG  
SP15       ------------------TTACATATATAGCACATCAAGATACAGGAAGATATCCAGAAG  
CPV-2      GAGAAACACCTGAGAGATTTACATATATAGCACATCAAGATACAGGAAGATATCCAGAAG  
                                 **     * *     * ** **** ******** ** * 
 
SP26       GAGAAGGGATTCAAAATAATACAATTACCCTTCGGGTATCAAATGATAANGTATTGCTAC  
SP20       GAGATTGGATTCAAAATATTAACTTTAACCTTCCTGTAACAGATGATAATGTATTGTTAC  
SP18       GAGATTGGATTCAAAATACTAACTTTAACCTTCCTGTAACAAATGATAATGTATTGCTAC  
SP1        GAGATTGGATTCAAAATATTAACTTTAACCTTCCTGTAACAAATGATAATGTATTGCTAC  
SP12       GAGATTGGATTCAAAATATTAACTTTAACCTTCCTGTAACAAATGATAATGTATTGCTAC  
SP15       GAGATTGGATTCAAAATATTAACTTTAACCTTCCTGTAACAAATGATAATGTATTGCTAC  
CPV-2      GAGATTGGATTCAAAATATTAACTTTAACCTTCCTGTAACAAATGATAATGTATTGCTAC  
           ****  ************ **   *** *****  *** ** ******* ****** *** 
 
SP26       CAACAGATCCAATTGGAGGTAAAACAGGAATTAACTATANTAATATATTTAATACTTATG  
SP20       CAACAGATCCAATTGGAGGTAAAACAGGAATTAACTATACTAATATATTTAATACTTATG  
SP18       CAACAGATCCGATTGGAGGTAAAACAGGAATTAACTATACTAATATATTTAATACTTATG  
SP1        CAACAGGTCCAATTGGAGGTAAAACAGGAATTAACTATACTAATATATTTAATACTTATG  
SP12       CAACAGATCCAATTGGAGGTAAAACAGGAATTAACTATACTAATATATTTAATACTTATG  
SP15       CAACAGATCCAATTGGAGGTAGAACAGGAATTAACTATACTAATATATTTAATACTTATG  
CPV-2      CAACAGATCCAATTGGAGGTAAAACAGGAATTAACTATACTAATATATTTAATACTTATG  
           ****** *** ********** ***************** ******************** 
 
SP26       GTCCTTTAACTGCATTAAATA---------------------------------------  
SP20       GTCCTTTAACTGCATTAAATAATGTACCACCAG---------------------------  
SP18       GTCCTTTAACTGCATTAAATAATGTACCACCAGTTTAT----------------------  
SP1        GTCCTTTAACTGCATTAAATA---------------------------------------  
SP12       GTCCTTTAACTGCATTAAATAATGTACCACCAGTTTATCCAAAT----------------  
SP15       GTCCTTTAACTGCATTAAA-----------------------------------------  
CPV-2      GTCCTTTAACTGCATTAAATAATGTACCACCAGTTTATCCAAATGGTCAAATTTGGGATA  
           *******************     
 
Figure 13. Section of the multiple alignment of positive samples successfully sequenced, along with 
the CPV-2 reference sequence (GenBank accession number: M38245). (Multiple aligned with Clustal 
Omega© tool; EMBL-EBI). 
Footnotes: underlined nucleotides: codon at Nt position 4062-4064, amino acid residue 426; yellow: 
different nucleotide highlighted, originating the codon “GAT”; *: same nucleotide presented in the 
nucleotide position.  
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Considering the sequence results, it was possible to group the sequenced samples under 
two strain groups, given the amino acid variation of canine and feline parvoviruses, at the 4062-
4064 nucleotide position (amino acid residue 426), which is a codon affected by SNPs (Table 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain (a) FPV / CPV-2a CPV-2b CPV-2c 
Codon observed (b) AAT GAT GAA 
    
Samples ID SP1; SP12; SP15; 
SP18; SP26 
SP20 -  
    
Number of sequenced 
samples (n=6) 
5 1 0 
Table 7. Parvovirus strain classification of the sequenced samples, accordingly to the codon observed 
at the amino acid residue 426, Nt position 4062-4064 (n=6). 
Table 7 footnotes: (a), (b): modified from Table 1. Amino acid variations in the VP2 protein of feline 
and canine parvoviruses (Adapted from Decaro N. et al., 2012 54). 
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7.3. Parvovirus Prevalence 
7.3.1. Overall Prevalence 
Considering the study population of cats held in the 13 rehoming centres, from the total 
of 818 faecal samples extracted and screened for FPV and CPV infection, 31 were PCR-positive. 
Prevalence = 31/818 = 0.0379 (95% confidence interval [CI], 0.0259 to 0.0534). 
The overall estimated prevalence of PCR-parvovirus positive faecal samples in the 
population was 3.8% (95% CI, 2.59 to 5.34% [31/818]). 
7.3.2. Centre Prevalence 
The prevalence of parvovirus PCR-positive faecal samples was calculated for each cat 
rehoming centre. Parvovirus was detected in at least one sample from 10 out of the 13 centres 
(95% CI, 46.19 to 94.96%), as represented in the Figure 14. No positive samples were detected 
in the cat shelters of St Helens, Mansfield, and Ferndown. 
The estimated prevalence in the sampled centres, which presented at least one positive, 
ranged between 20.5% (95% CI, 11.98 to 31.62%) in Dereham, and 1.28% (95% CI, 0.03 to 
6.94%) in Truro (Table 8). 
  
  
 
 
 
Centre Prevalence (% [no. parvovirus positive/total no.]) 95% CI (%)a 
Dereham 20.5 (15/73) 11.98 – 31.62 
Hereford 4.65 (2/43) 0.57 – 15.81 
Downham Market 3.53 (3/85) 0.73 – 9.97 
Haslemere 3.23 (1/31) 0.08 – 16.70 
York 2.63 (1/38) 0.07 – 13.81 
Bridgend 2.50 (2/80) 0.30 – 8.74 
Birmingham 2.43 (4/164) 0.67 – 6.13 
Exeter 2.38 (1/42) 0.06 – 12.57 
Isle of Wight 1.37 (1/73) 0.03 – 7.4 
Truro 1.28 (1/78) 0.03 – 6.94 
St Helens 0 (0/54) 0 – 6.6 
Mansfield 0 (0/30) 0 – 11.57 
Ferndown 0 (0/27) 0 – 12.77 
Table 8. Prevalence of parvovirus positive faecal samples in different centres. 
Table 8 footnotes: (a) 95% CI, 95% Confidence Interval. 
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Map Legend: 
Parvovirus detected in cats 
of the centres of: 
(green) 
1. York 
4. Birmingham 
5. Downham Market 
6. Dereham 
7. Hereford 
8. Bridgend 
9. Truro 
10. Exeter 
12. Isle of Wight 
13. Haslemere 
 
Parvovirus not detected in 
cats of the centres of: 
(red) 
2. St Helens 
3. Mansfield 
11. Ferndown  
 
 
Figure 14. Geographical location of the cats rehoming centres, according to the detection of parvovirus. Map 
generated with ArcGIS™ (Esri®). 
Footnotes:  
numbers in green: location of the cat rehoming centres where parvovirus was detected (n=10);  
numbers in red: location of the cat rehoming centres where parvovirus was not detected (n=3). 
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8. Discussion  
 
This study represents the first population-based study of parvovirus prevalence in the UK 
since 2012. It is known that CPV strains have evolved and can infect and cause disease in cats. 
This study provides evidence of infection by parvoviruses in a non-clinical cat population across 
UK. 
Parvoviruses were detected at a low prevalence (3.8%) in this apparently healthy cat 
population in the UK, considering the 13 rehoming centres sampled, which comprised 818 
samples.  
 Parvoviral infections were reported in asymptomatic cats in the UK in a previous study101, 
and a high prevalence of  parvoviral shedding was reported in apparently healthy cats (33%), 
which contrasts sharply with overall prevalence found in this study. The prevalence found in the 
present study, in centres that presented at least one positive sample, ranged between 20.50% 
and 1.28%, with twelve of the 13 centres presenting a prevalence for parvovirus faecal shedding 
of less than 5%, suggesting that the results could be highly dependent on timing and location of 
sampling. Significantly, ten out of 13 centres housed at least one cat shedding parvovirus 
(parvovirus-positive cat). 
In other countries, such as India and China, the prevalence found for CPV/FPV infections 
in cats ranged between 11% and 12.5%. Considering that these studies have included both 
asymptomatic and clinical affected cats, the prevalence reported is more in line with the estimated 
prevalence found in the present study in the UK. Additionally, these studies mentioned that 
preventive measures and vaccination are still  uncommon  in those areas, which is likely to 
contribute for a higher prevalence.121,122 
Interestingly, it is possible to compare the low prevalence of parvoviruses asymptomatic 
infection found in this study with other viral agents in the same cat population, namely the feline 
rotaviruses. Indeed, this specific sample collection was previously included in a broad study of 
rotaviruses, which included not only the 13 rehoming centres tested in this study for FPV/CPV, 
but the total of the 25 rehoming centres in the UK. The estimated prevalence of feline rotaviruses 
in the cat population was 3.0%.129 This is interestingly similar to the prevalence of 3.8% for 
parvoviral asymptomatic infection found in this study, considering that the present study reflects 
a substantial proportion of the same population. 
The study suggests a low national prevalence of parvovirus in the cat population as the   
prevalence of infection found was 3.8% and the cross-sectional sampling provided a snapshot 
view across the UK.  
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 Longitudinal sampling methods based on this estimated prevalence could be used to 
better understand transmission. Additionally, longitudinal sampling could be useful to determine 
whether the cats of non-clinical populations act as long-term carriers. 
The higher prevalence for parvovirus faecal shedding was found in the Dereham centre 
(20.5%) may arise from a spread within a centre or reflect the income of cats already infected and 
shedding parvoviral particles due to an outbreak in the local area. It has been suggested that high 
shelter prevalence is mainly driven by incoming infected cats, which reflects the FPV/CPV 
infection in the general feline population.101 Limited evidence for transmission within the centre is 
also consistent with previous studies of FCV, an important respiratory pathogen of cats, in similar 
shelters.132 In addition, this result cannot be related to sample contamination, since the samples 
were carefully processed, with a rigorous use of negative controls, and all the positive samples 
were double-checked in a separate reaction using the initial DNA extraction 
Viral diseases, especially gastrointestinal pathogens are not easily contained, and 
biosecurity procedures are essential to infection spread control within shelters environments.41 
Biosecurity measures for the cat rehoming centres are described to be high standard across the 
country, as all shelters apply strict hygiene guidelines.129 Therefore, that may also reflect the  low 
prevalence found for FPV/CPV faecal shedding in the tested shelters. 
Further investigation would allow completion of the analysis of the collection of samples 
from the 25 rehoming cat centres across the UK, which would allow inference of a prevalence of 
all centres. Additionally, a more reliable and broad conclusion about the national prevalence of 
parvoviruses asymptomatic infection in the UK cat population could be estimated, as more distinct 
locations can be included in the study, such as Northern Ireland (shelter of Belfast) and Scotland 
(shelter of Glasgow). Additionally, epidemiological data, such as the age of the cats and faecal 
consistency of the samples can be associated with the population, which may be considered as 
valuable epidemiological variables to further characterize the parvoviral infection in this non-
clinical feline population. 
The use of a shelter cat population as a sentinel for the cat population in the UK may be 
considered a study limitation, as a shelter feline population rather than owned cats may have 
associated stressors and increased opportunities for disease spreading, considering the densely 
populated environment with cats from diverse backgrounds, and the constant flux of animals. 
However, it has been described that the majority of the study population is comprised of healthy 
cats that have been abandoned from homes due to socioeconomic factors, and consequently, 
true strays represent a minority of the population. Feral cats are only sporadically and temporarily 
housed in the shelters for trap-neuter-release programmes. Therefore, the use of these centres 
is considered a valid comparison and a reflection of the cat owned population in the UK.129 
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The molecular analysis of positive samples provided an insight into the molecular 
characterisation of the circulating field variants of parvoviruses in the feline population across the 
country. In the present study, five FPV/CPV-2a-like variants and one CPV-2b strain were 
identified, considering the spanning of the amino acid residue 426 position. Therefore, the 
identification of one CPV-2b variant evidences that CPV-2 variants are present in clinically healthy 
cats in the United Kingdom. Further studies would allow to obtain additional genetic information 
on these isolates, particularly the differentiation between FPV and CPV-2a variants, using a PCR 
assay specifically designed to obtain genetic data on different and extended key-position sites of 
the VP2 viral gene. The development of other PCR assays, specifically designed to obtain full-
length amplification of the VP2 gene, would also be useful in an attempt to identify possible 
mutations and to proceed to viral phylogenetic analysis, which could be advantageous to better 
understand the epidemiological aspects such as field selection pressure on parvoviruses of the 
cat population.  
The use of a previously-designed conventional PCR assay to screen and detect 
FPV/CPV-2 strains in a large number of tested samples was convenient due to the limited time 
available to this project, and it fulfilled the main goal of generating an insight about the 
epidemiological situation of parvoviruses in the shelter cat population. In-house experiments 
before the study course have attested the reliability of the established assay conditions. None the 
less, in further studies, the use of real-time PCR technology could be beneficial to obtain 
quantitative data, since low shedding titres are expected in this type of population, without overt 
clinical disease. Further investigation would allow measurement of viral DNA load in faeces and 
to determine whether DNA viral loads correlate with clinical signs, such as diarrhoea, to be 
determined through further inputs of the epidemiological data. Additionally, it would be possible 
to determine whether DNA sequencing information and certain genotypes are related to disease 
severity.  
The presence of faint but specific electrophoresis bands, as shown in the results analysis, 
can be explained by the presence of low parvoviral DNA load, which is indeed expected in a 
population without overt clinical signs. Further investigation using real-time PCR methods would 
be beneficial, as it is more sensitive than conventional PCR coupled with agarose electrophoresis 
gels. 
Vaccination status of the population was not considered in this study, however it is 
described that post-vaccinal faecal shedding can be detected, interfering with diagnostic 
assays.43 Further investigation could allow determining  to what extent low titres of MLV vaccines 
are shed by cats in this feline population, which could potentially cause an overestimated 
prevalence of parvoviral infection  Additionally, further studies are needed to better understand 
the interaction in the field between CPV infection and FPV vaccination in cats.  
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It has been described that cats may be able to shed CPV/FPV for relatively prolonged 
periods of time, as an asymptomatic infection, and are more likely to be chronically infected rather 
than experiencing repeated rounds of infection-clearance-reinfection.101 Indeed, although 
parvoviruses are normally associated with acute infections, longer  infection courses  have been 
reported.133 It was shown in experimentally infected cats that FPV can be shed in urine and faeces 
up to 42 days post infection.133 In mink, faecal shedding of MEV, a closely related virus of both 
CPV and FPV, has been demonstrated for up to one year, suggesting that adult mink may become 
asymptomatically infected, and may act as reservoirs.134 The virus hiding in intestinal epithelial 
cells beyond the reach of antibodies is eliminated in the faeces, as these cells are continuously 
desquamated.101 Infection persistence is also a characteristic of human parvovirus B19.101,135  
Clinically normal long-term shedders have been considered important to identify in 
attempts to control or eradicate these diseases in both dog and cat populations.101 Further studies 
are needed to clarify the potential of cats as reservoirs for parvoviruses, and to determine its 
mechanism and dynamics. 
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9. Conclusion 
 
Diseases surveillance has been lacking in UK companion animal populations, despite the 
estimated population of more than 11 million dogs and 10 million cats in the country. 
In summary, the present study provides an updated and valuable insight into the 
surveillance of parvoviruses in the cat population in the UK.  The surveillance of parvoviruses in 
feline populations is important for investigating parvovirus genetic diversity, elucidating the role of 
asymptomatic carriage, and monitoring the risk of infection and outbreak situations of this evolving 
and emerging disease in the pet population in the UK. 
Moreover, this study raises different concerns about the control of parvovirus infection in 
both cats and dogs, namely, whether these observations are reproductible in other cat 
populations, which transmission dynamics occur in the field, particularly, whether the viruses are 
transmissible between cats and dogs, and whether they are able to cause disease in 
unvaccinated populations. Intensifying surveillance of parvoviruses in both cat and dog population 
is required. 
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III. Appendix Section 
A1. A study of UK Rottweiler owners/breeders’ opinions about vaccination –  
Preliminary Report of Results 
 
Information Notice 
During the traineeship at the School of Veterinary Medicine and Science, University of 
Nottingham, a contribution was made to this project. Dr. Mark Dunning developed and conducted 
the survey, and the Trainee (Ivo Fins) have conducted the result analysis as part of his training 
activities, resulting in the present preliminary report of results. 
Further analysis, discussion of results, and development of the project are planned, 
however outside of the traineeship scope. 
Additionally, an abstract has been submitted, with the participation of the Trainee (Ivo 
Fins) as first author, and it has been accepted for oral presentation at the British Small Animal 
Veterinary Association (BSAVA) Congress 2018. 
Introduction 
Among other dog breeds, Rottweilers have been reported to have a high susceptibility to 
parvovirus infection, however evidence to support this have been lacking. Whilst, in the United 
Kingdom, the 2017 PDSA Animal Wellbeing (PAW) Report have stated that 25% of the dogs have 
not had a primary vaccination course when young, compromising 1814 dog owners surveyed in 
the country. 
Aim 
To better understand vaccination practices in UK Rottweilers, according to the responses 
of Rottweiler owners/breeders.  
Methods 
The survey was conducted from March 2016 to May 2017. It registered 624 total 
respondents, all of which were Rottweilers’ owners/breeders. 
A simple quantitative method was used in the majority of the results’ analysis, with the 
exception of the open-ended questions, where the tendency of answers by topic was identified. 
Whenever possible, the answers were categorized. 
The results of each question and a keynote analysis are presented below. 
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Results 
1. Please state how many dogs you currently own: 
 
 
 
 
The total number of Rottweilers included in this study is 1214 (Table 9), with an average 
number of 2 Rottweilers per owner (Chart 1). 71% of the owners have also other dogs’ breeds, 
classified as Non-Rottweilers. 
2. Have ever had dogs / litters affected by parvovirus? 
 
 
 
 
 
Chart 1. Average number of dogs owned by the 
respondents. 
Table 9. Average and total number of dogs and relative frequencies of answers 
to the question one. 
Chart 2. Percentage of dogs/litters affected by 
parvovirus. 
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The majority of respondents have never had dogs or litters affected by parvovirus (89.7%) 
(Chart 2 and Table 10). 
3. If yes, please give details including the outcome. 
From a total of 69 responses, approximately 63% describe successful recovery of parvovirus 
cases, with hospitalization. 
In several answers is possible to know in what age the parvovirus infection occurred, being 
possible define the most common time frame when parvovirus cases occur, which was between 
the 6 weeks and 1-year old. 
Nine responses from the 69 answers were excluded due to not presenting any information 
(N/A), or due to not give details on the clinical outcome or age of the dogs. 
4. Do you routinely have your Rottweilers vaccinated against any of the following 
diseases? (please select all that apply) 
 
  
Table 10. Relative frequencies of answers to the question two. 
Chart 3. Percentage of answers distributed by vaccination 
option/disease. 
  
70 
 
 
Approximately 47% from a total of 569 respondents answered as recommended by the 
Vet (Table 11). 
It is important to highlight that almost 35% of the respondents said that they do not 
routinely vaccinate their Rottweilers after the initial vaccination course (Chart 3). 
Parvovirus was the most frequent individual disease vaccinated against with around 25% 
of responses. 
Approximately 4% of the owners/breeders respond that do not routinely vaccinate their dogs. 
5. If not, please give details as to why not. 
 Around 38% of the respondents agree with the initial course of puppy vaccination.  
 33% of the 214 respondents describe worries about over vaccination and vaccination 
boosters, affirming that vaccination boosters are not necessary, and could be just a money-maker 
by veterinarians and pharmacological companies.  
 Around 14% of the answers mention titre testing to decide the vaccination course. 
 11% of the respondents mentioned cases of adverse reaction to vaccination or immunity 
disorders caused by vaccination. 
 It is important to highlight that some owners/breeds present their worries about the use 
of chemicals and possible links with autoimmune diseases and cancer. 
 Less than 5% of the answers support the use of natural medicines and homeopathic 
nosodes instead of vaccination. 
 Several respondents allude to evidence that could support the dangers of over 
vaccination, including vaccination studies, seminars and other sources of knowledge. 
Table 11. Relative frequencies of answers to the question four. 
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6. Do you vaccinate your dog with the Kennel cough vaccine against Bordetella? 
 
 
 
 
63% of the 611 responders answered that they do not vaccinate their dogs with the 
Kennel cough vaccine against Bordetella (Table 12). 
Approximately 37% responders indicate that they vaccinate their dogs with the Kennel cough 
vaccine (Chart 4). 
 
7. Please give details as to why/why not. 
The majority of the 455 respondents affirm this vaccination is not needed, or it is only 
necessary if their dogs are going into kennels or in contact with several dogs regularly (e.g. dog 
shows). 
Owners with dogs that are kennelled regularly answered that they vaccinate their dogs 
with the Kennel Cough vaccine, as a requirement of boarding kennels and as a precaution. 
Around 13% of the respondents believe the Kennel Cough vaccine is not very effective, 
because just cover a minimal number of strains, which do not convince the respondents that the 
vaccination is in fact need it. 
 
 
Chart 4. Percentage of answers regarding Kennel cough 
vaccination. 
Table 12. Relative frequencies of answers to the question six. 
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8. Do you have the same strategy for vaccinating any non-Rottweiler dogs you own? 
 
 
 
 
 
 
89.6% of the 195 respondents affirm that they have the same strategy for vaccinating any 
non-Rottweiler dog they own (Chart 5, Table 13). 
9. If no, please give details of the difference. 
For the majority of the respondents, the question is not applicable as they do not own 
other dogs. 
In the considered answers are identified several reasons that describe non-vaccination, 
such as only vaccinate due to dog shows, the owners no longer vaccinate any dogs they own, 
non-Rottweiler dog has a compromised immune system, and the non-Rottweiler dog is not 
insured. 
 
 
 
 
 
Chart 5. Percentage of answers regarding the strategy for 
vaccination non-Rottweiler dogs owned by the 
respondents. 
Table 13. Relative frequencies of answers to the question eight. 
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10. Do you follow the vaccination schedule recommended by your vet? 
 
 
 
 
 
Approximately 60% of the respondents affirm that they follow the vaccination schedule 
recommended by their Vet, against almost 40% that affirm not follow the schedule recommended 
by the Vet (Chart 6, Table 14). 
 
11. If no, please comment on why not and give details of any other schedule you 
follow:  
The majority of the respondents consider that dogs are over vaccinated if they would 
follow a vaccination schedule. Thus, most of the respondents affirm to follow a first course 
vaccination to puppies, but not the recommended boosters. 
Around 14% of the 219 answers mention titre testing instead of following a restricted 
vaccination schedule. 
Homeopathic nosodes are also mentioned as an alternative to vaccination. 
 
 
 
Chart 6. Percentage of answers regarding the vaccination 
schedule recommended by the vet. 
Table 14. Relative frequencies of answers to the question ten. 
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12. How often do you re-vaccinate after the initial puppy vaccination course? 
 
  
 
 
 Approximately 46% of the 611 respondents affirm that they re-vaccinate annually after 
the initial vaccination, and about 14% follow the Vet recommendations (Chart 7, Table 15). 
 Around 40% of the respondents identify their situation as other. 
13. If you have answered ‘other’, please comment (e.g. no boosters, every 3 years): 
 The main tendency of answer is no boosters after the puppy initial course, including some 
answers that mention the inclusion of the first-year booster, and no more vaccination after that. 
 In 12% of the 250 answers is possible to identify titre testing habits or intention in have 
immunity levels checked before deciding for vaccination.  
 Isolate answers (not a tendency of answer) mention no vaccination at all; cases of 
vaccination just when is required by kennels policy; the use of homeopathic products, or to follow 
advices given by holistic “veterinarians”. 
 Five (5) responses were excluded due to mention that the answer was the same replied 
on other questions (report produced using aggregated data per question). 
 
Chart 7. Percentage of answers regarding the re-vaccination 
after the initial vaccination course. 
Table 15. Relative frequencies of answers to the question twelve. 
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14. Have you ever had blood samples taken before or instead of vaccinations to 
determine if your dog/s have an adequate level of immunity? 
 
 
 
 
Approximately 83% of the 616 respondents did never have blood samples taken before 
or instead of vaccinations to determine if their dog/s have an adequate level of immunity (Chart 
8, Table 16). 
 
15. Has your veterinarian ever recommended having blood samples taken before 
vaccination to determine if your dog/s have an adequate level of immunity? 
 
  
Chart 8. Percentage of answers regarding the determination 
of level of immunity before vaccination. 
Table 16. Relative frequencies of answers to the question fourteen. 
Chart 9. Percentage of answers regarding the recommendation 
for determine the level of immunity before vaccination. 
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97% of the 610 respondents affirm that their veterinarian never had recommended having 
blood samples taken before vaccination to determine if their dog/s have an adequate level of 
immunity (Chart 9, Table 17). 
 
16. Do you use any non-veterinary based products/natural remedies to aid with 
preventing any of the diseases usually protected with vaccinations?  
 
 
 
 
 
 
 
Approximately 89% of the 612 respondents affirm that do not use any non-veterinary 
based products/natural remedies to aid with preventing any diseases usually protected with 
vaccinations, against 11% that affirm to use non-veterinary products (Chart 10, Table 18). 
 
 
Table 17. Relative frequencies of answers to the question fifteen. 
Chart 10. Percentage of answers regarding the use of non-
veterinary based products/natural remedies. 
Table 18. Relative frequencies of answers to the question sixteen. 
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17. If yes, please provide further details of what these are and why these are used? 
The majority of the 64 answers mention the use of homeopathic nosodes, although is 
also possible identify the use of supplementation like as pro-biotics, Diatomaceous Earth, 
Turmeric, Ainsworth, Hilton supplement, Benelyn, Golden Paste, Omnious and MSM Riaflex. 
Natural supplements given for miscellaneous conditions include coconut oil, flaxseed and 
pumpkin seeds, seaweed, garlic, soya bean, banana extract and honey. 
 
18. Have you ever felt your dog has been unwell after their vaccinations? 
 
 
 
 
Around 68% of the 617 respondents had never felt their dog has been unwell after their 
vaccinations, against approximately 32% affirm that had happen (Chart 11, Table 19).  
 
19. If yes, please give details of the clinical signs exhibited, when they started and for 
how long the signs persisted? 
Considering the 197 answers, the most frequently clinical sign is lethargy. Other frequent 
clinical signs include anorexia, vomits, diarrhoea, and oedema at the vaccine inoculation site. 
Mainly, the described signs persisted for 1 to 2 days. 
Secondary consequences (presumably related with vaccination) and adverse reactions 
include immune-mediated meningitis, paralysis, immune-mediated arthritis, collapse followed by 
recover, colitis, skin hotspots, ulcerated skin lesions, scratching, and interdigital cysts. 
Chart 11. Percentage of answers regarding the malaise of dogs 
after vaccination.  
Table 19. Relative frequencies of answers to the question eighteen. 
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20. If you are a breeder do you recommend vaccinating any puppies that you sell on 
as pets? 
 
 
 
 
 
 
Around 77% of the 193 respondents, as breeders, say that they recommend vaccinate 
puppies they sell as pets. Even so, 23% do not recommend vaccinate the puppies they sell (Chart 
12, Table 20). 
21. If no, please give further details as to why and what you recommend instead: 
Around 33% of the breeders recommend the first vaccination course (puppy vaccination) 
only.  
Additionally, approximately 27% of the answers recommend titre testing instead of 
booster vaccination. 
24% of the respondents says that they leave to the owners’ decision, or advise them to 
do their own search for information about vaccination, sometimes presenting their personal point 
of view. 
10% of the respondents describe worries about compatibility of different vaccine brands 
used by different vets. 
6% of the respondents recommend the use of homeopathic nosodes, or do not vaccinate. 
Twenty-five (25) of the 74 answers were excluded due to not applicable information (N/A) 
(non-breeders). 
Chart 12. Percentage of answers regarding the recommendation 
of vaccinate sold puppies. 
Table 20. Relative frequencies of answers to the question twenty. 
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22. If you bought your Rottweiler from a breeder, did they provide any advice about 
vaccination? 
 
 
 
 
 
 53% of 458 respondents affirm that they did not receive any advice about vaccination 
from the breeder, against 47% that affirm received advices from the breeder about vaccination 
(Chart 13, Table 21). 
23. If yes, please give further details.   
 39% of the respondents affirm that the breeders only provide information about the 
vaccination scheme on course and/or when was due the next vaccine. 
 Approximately 25% of the owners mention that it was recommended the initial vaccination 
course only. 
 Around 13% of the owners were advised to have yearly boosters done. 
 Additionally, around 12% of the owners have received advices to discuss with the vet the 
vaccination theme, or to follow the vet recommendations on the matter. 
 Approximately 6% of the owners affirm that they have received recommendations for titre 
testing.  
 Less than 5% of the answers include advices to use homeopathic products, or no 
vaccinate their dogs, or do not vaccinate against Leptospirosis/do not use Lepto4.  
Chart 13. Percentage of answers regarding the provision of 
advises about vaccination. 
Table 21. Relative frequencies of answers to the question twenty-two. 
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 Thirty-seven (37) of the 202 answers were excluded due to no present any applicable 
information (N/A), or declare that do not have received any advice, or the dog does not have 
come from a breeder (i.e. shelters, rescues). 
 
